Page last updated: 2024-11-04

alanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alanine is a non-essential amino acid, meaning that the human body can synthesize it. It is a building block for proteins and plays a role in various metabolic processes, such as glucose metabolism and the synthesis of other amino acids. Alanine is found in many foods, including meat, poultry, fish, dairy products, and beans. Research on alanine focuses on its potential therapeutic applications, such as in the treatment of muscle wasting conditions and liver diseases. Alanine is also studied for its role in regulating blood glucose levels and its potential contribution to the development of certain diseases, including diabetes and cancer.'

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5950
CHEMBL ID279597
CHEBI ID16977
MeSH IDM0000619
PubMed CID602
CHEMBL ID12198
CHEBI ID16449

Synonyms (273)

Synonym
AC-014
l-alanine, labeled with carbon-14
14c-l-alanine
(c14)l-alanine
gtpl720
l-ala
AKOS015840030
(s)-2-aminopropionic acid
alanina
CHEBI:16977 ,
(s)-2-aminopropanoic acid
l-alanin
D00012
alanine (usp)
l-alanine (jp17)
nsc 206315
alanine (van)
alanina [dcit,spanish]
(l)-alanine
einecs 200-273-8
propanoic acid, 2-amino-, (s)-
alaninum [latin]
alanine [usan:inn]
tocris-0205
NCGC00024494-01
l-2-aminopropanoic acid
(s)-alanine
.alpha.-alanine
nsc-206315
l-.alpha.-aminopropionic acid
propanoic acid, 2-amino-
l-.alpha.-alanine
.alpha.-aminopropionic acid
alanine, l-
propanoic acid, 2-amino-, (s)
(s)-alpha-aminopropionsaeure
alpha-aminopropionic acid
l-(+)-alanine
l-alpha-aminopropionic acid
hsdb 1801
l-alanine (9ci)
2-aminopropanoic acid, l-
(s)-(+)-alanine
(s)-2-aminopropionsaeure
l-s-aminopropionic acid
alpha-alanine
l-2-aminopropionsaeure
alanine, l- (7ci,8ci)
l-&alpha-alanine
l-2-aminopropionic acid
L-ALPHA-ALANINE ,
2-aminopropionic acid
alanine
C00041
l-alanine ,
56-41-7
(2s)-2-aminopropanoic acid
l-alanine, >=98% (tlc)
l-alanine, >=99%
l-alanine, from non-animal source, meets ep, usp testing specifications, suitable for cell culture, >=98.5%
DB00160
F4F207FF-8FF8-4789-99A1-147AE0A36673 ,
A0179
h-ala-oh
BMSE000028
CHEMBL279597 ,
77160-91-9
bdbm50000099
115967-49-2
A803529
(2s)-2-azanylpropanoic acid
A15652
(s)-2-aminopropanoic acid;h-ala-oh
unii-of5p57n2zx
ec 200-273-8
of5p57n2zx ,
alaninum
130380-93-7
26336-61-8
BMSE000994
l-a-aminopropionic acid
a-alanine
a-aminopropionic acid
l-a-alanine
l-alanine, labeled with tritium
AKOS010367904
25191-17-7
BP-13281
AM20100374
l-alanine [jan]
alanine [inn]
lysine acetate impurity c [ep impurity]
l-alanine [fcc]
alanine [usp monograph]
serine impurity a [ep impurity]
valine impurity a [ep impurity]
alanine [vandf]
alanine [who-dd]
l-alanine [usp-rs]
alanine [hsdb]
alanine [mi]
alanine [ii]
alanine [ep monograph]
alanine [usan]
alanine [inci]
S5631
gtpl4542
[14c]-alanine
gtpl4543
[3h]-alanine
[3h]alanine
[14c]alanine
ala-oh
racemic alanine
6898-94-8
3h-l-alanine
Q-201274
ritalanine
l-ch3ch(nh2)cooh
AC-24031
l-alanine, cell culture reagent (h-l-ala-oh)
mfcd00064410
F0001-2354
alanine, european pharmacopoeia (ep) reference standard
sr-01000597687
SR-01000597687-3
l-alanine, certified reference material, tracecert(r)
l-alanine, saj special grade, >=99.0%
l-alanine, bioultra, >=99.5% (nt)
l-alanine, united states pharmacopeia (usp) reference standard
l-alanine, purum, >=98.0% (nt)
l-alanine, >=99.0% (nt)
D84362
l-alanine, pharmaceutical secondary standard; certified reference material
l-alanine, 99%, natural, fg
alanine (l-alanine)
J-015860
l-2-aminopropionate
a-aminopropionate
alpha-aminopropanoate
l-alpha-aminopropionate
2-ammoniopropanoic acid
alpha-aminopropanoic acid
l-2-aminopropanoate
(s)-2-amino-propanoic acid
(s)-2-amino-propanoate
alpha-aminopropionate
l-a-aminopropionate
(s)-2-aminopropanoate
HY-N0229
l alanine
alanine, l isomer
alanine, l-isomer
l-isomer alanine
CS-W020002
DTXSID20873899 ,
l-alanine,(s)
Q218642
EN300-52621
STR01663
CCG-266017
l-alanine powder
l-ala-2
STARBLD0003382
valine impurity a (ep impurity)
alaninum (latin)
alanine (ii)
lysine acetate impurity c (ep impurity)
serine impurity a (ep impurity)
alanine (ep monograph)
dtxcid001012092
alanine (usp monograph)
Z756424912
2-amino-propionic acid
d,l-alanine
nsc-7602
alanine, dl-
dl-.alpha.-alanine
dl-.alpha.-aminopropionic acid
nsc7602 ,
(.+-.)-alanine
dl-alanine
alanine, alpha
dl-2-aminopropanoic acid
alanin
CHEBI:16449 ,
(.+/-.)-alanine
dl-alpha-aminopropionic acid
(+-)-alanine
ai3-08908
einecs 206-126-4
dl-alpha-alanine
nsc 7602
dl-2-aminopropionic acid
(r,s)-alanine
(+-)-2-aminopropionic acid
(rs)-2-aminopropionsaeure
l(+)-alanine
nsc206315
2-aminopropanoic acid
302-72-7
C01401
nsc-158286
d(-)-.alpha.-alanine
nsc158286
dl-alanine, >=99% (hplc)
dl-alanine, >=99%, fcc, fg
STK125106
915B7CC8-31B0-4478-904B-D54B7ECC1E4D
A0178
h-dl-ala-oh
L001042
BMSE000282
CHEMBL12198
e639
FT-0657966
FT-0693448
FT-0661451
AKOS000119663
ccris 8596
1fu7983t0u ,
unii-1fu7983t0u
A820286
FT-0627654
FT-0625418
FT-0625415
FT-0624399
AM20090411
AB02601
fema no. 3818
dl-alanine [fcc]
(+/-)-2-aminopropanoic acid
(+/-)-2-aminopropionic acid
(+/-)-alanine
alanine dl-form [mi]
2-amino propanoic acid
dl-ala
(dl)-alanine
AKOS016039389
SY002277
AKOS024264604
l-alanine-2-13c-15n
alanine #
alanine, .alpha.
Q-101653
l-|a-aminopropionic acid
l-alanine extra pure
(r)-(-)-2-aminopropionic acid
l-alanine-15n;25713-23-9;h-[15n]ala-oh;332127_aldrich
mfcd00064408
DTXSID6031255
Z57396987
F1652-0639
dl-alanine, fcc, >=99%
dl-alanine, vetec(tm) reagent grade, 98%
l-alanine (3-13c)
(a-d-mannosyl)7-b-d-mannosyl-diacetylchitobiosyl-l-asparagine, isoform a (protein)
(alpha-d-mannosyl)7-beta-d-mannosyl-diacetylchitobiosyl-l-asparagine, isoform a (protein)
dl-aminopropionic acid,(s)
Q27101911
BCP26675
EN300-18224
BCP31944
h-d-ala-oh;(r)-alanine;(2r)-2-aminopropanoic acid
SY005245
CS-0022544
D72543
l-alanine (d7)
dl-alanine (3-13c)
HY-N2362
dl-alanine (2-13c)
l-alanine-c2
alanine-1,2,3-13c3

Research Excerpts

Toxicity

Agonists of the glycine recognition site of NMDA receptors (D-serine and D-alanine) did not have any toxic effect in hippocampal cultures. A rise in alanine and aspartate aminotransferases and the development of infections were the most frequent adverse events.

ExcerptReferenceRelevance
" The combination of cephalosporins with aminoglycosides increases the potential toxic effect on the proximal tubule."( Tubular-toxic effects of aminoglycosides and their combinations with cephalosporins.
Bindzi, C; Breier, J; Hendus, J; Maske, L; Mondorf, AW; Scherberich, JE; Schoeppe, W, 1979
)
0.26
" Dose-dependent metabolism of methotrexate is unusual in that formation of the presumed toxic metabolite increases with increase in dose and is associated with a qualitative change in the pattern of drug toxicity at high compared to low doses of drug."( Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Powis, G, 1983
)
0.27
" The LD50 of L-alanosine (given intraperitoneally) was approximately 2 g/kg; L-5178Y/AR tumor, small intestine, liver, and lung were the tissues more consistently or severely damaged by the drug."( Determinants of the toxicity of L-alanosine to various organs of the mouse.
Cooney, DA; McGee, E; Thake, DC; Tyagi, AK, 1981
)
0.26
"Ricin is a toxic glycoprotein made of two polypeptide chains (A and B) linked by a disulfide bond."( Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies.
Mohanraj, D; Ramakrishnan, S, 1995
)
0.29
" Valproate caused a dose-dependent increase in leakage of lactic acid dehydrogenase (LDH), and glycine prevented this toxic response."( Effect of glycine on valproate toxicity in rat hepatocytes.
Gray, PD; Tolman, KG; Vance, MA,
)
0.13
" In contrast to the general tendency in hydrophobicity-toxicity relationships, replacement of Asn27 yielded a more hydrophobic but less toxic analog and that of Met35 gave a less hydrophobic but more toxic one."( Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25-35) peptide as analyzed by single alanine substitution.
Imahori, K; Maeda, T; Noguchi, K; Sato, K; Takashima, A; Wakamiya, A, 1995
)
0.29
" DL-Buthionine-[S,R]-Sulfoximine (BSO) and Diethyl maleate (DEM) were used to potentiate the toxic effect of the bipyridyl."( Biochemical studies on the toxicity of 1, 1'-dimethyl-4, 4'-bipyridylium dichloride in the rat.
Nwabisi, VC; Nwanze, EA, 1997
)
0.3
"To develop the safe formulation that can safely improve bioavailability of poorly absorbable drugs and that is practically available, we prepared the suppositories of rebamipide, a poorly soluble and poorly absorbable antiulcer drug, by employing the combinatorial use of sodium laurate (C12), an absorption enhancer, with taurine (Tau) or L-glutamine (L-Gln), an adjuvant exerting the cytoprotective action."( Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine.
Higaki, K; Kamada, N; Kimura, T; Minami, T; Miyake, M; Mukai, T; Odomi, M; Ogawara, K; Oka, Y; Toguchi, H, 2004
)
0.32
" Agonists of the glycine recognition site of NMDA receptors (D-serine and D-alanine) did not have any toxic effect in hippocampal cultures, whereas competitive blockade of the glycine site by 7-chlorokynurenic acid was neuroprotective."( Glycine-induced neurotoxicity in organotypic hippocampal slice cultures.
Barth, A; Barth, L; Newell, DW; Nguyen, LB, 2005
)
0.33
" Adverse events reported by subjects taking 5-mg, 20-mg, or 40-mg doses were similar to those reported by subjects taking placebo."( Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.
Dean, RA; Farlow, M; Gonzales, C; May, PC; Ness, D; Satterwhite, J; Siemers, E; Skinner, M,
)
0.13
"Azathioprine (aza) therapy is beneficial in the treatment of inflammatory bowel disease, but 10%-30% of patients cannot tolerate aza therapy because of adverse drug reactions."( Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.
Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2005
)
0.33
" The test compound used was the metabotropic glutamate receptor antagonist, L(+)-2-amino-3-phosphonopropionic acid (L-AP3), which is known to be toxic in vivo after subchronic, but not acute, administration."( Long-term, repeated dose in vitro neurotoxicity of the glutamate receptor antagonist L-AP3, demonstrated in rat hippocampal slice cultures by using continuous propidium iodide incubation.
Blaabjerg, M; Kristensen, BW; Noraberg, J; Zimmer, J, 2007
)
0.34
" With the possible exception of headache, no clinically significant adverse events or laboratory changes were observed."( Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Dean, RA; Farlow, MR; Ferguson-Sells, L; Friedrich, S; Gonzales, C; May, PC; Siemers, ER,
)
0.13
"Primary outcome measures were adverse events, plasma and cerebrospinal fluid Abeta levels, vital signs, electrocardiographic data, and laboratory safety test results."( Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Aisen, PS; Becerra, L; Clark, CM; Dean, RA; Farlow, MR; Fleisher, AS; Galvin, JE; Peskind, ER; Quinn, JF; Raman, R; Sherzai, A; Siemers, ER; Sowell, BB; Thal, LJ, 2008
)
0.35
" There were 3 adverse event-related discontinuations, including 1 transient bowel obstruction."( Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Aisen, PS; Becerra, L; Clark, CM; Dean, RA; Farlow, MR; Fleisher, AS; Galvin, JE; Peskind, ER; Quinn, JF; Raman, R; Sherzai, A; Siemers, ER; Sowell, BB; Thal, LJ, 2008
)
0.35
" No difference in the incidence of adverse events was seen between the two groups, confirming the safety of rebamipide."( Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial.
Kawakami, A; Koni, I; Nishinarita, M; Nishiyama, S; Ohta, S; Oka, H; Sawada, S; Sugai, S; Sugiyama, E; Takahashi, H; Takei, M; Umehara, H; Yamaji, K, 2009
)
0.35
"We report the establishment of an in vivo model using the fruit fly Drosophila melanogaster to investigate the toxic effects of L-BMAA."( BMAA neurotoxicity in Drosophila.
Bradley, WG; Escala, W; Papapetropoulos, S; Zhai, RG; Zhou, X, 2009
)
0.35
" Most toxic effects were mild."( A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
de Braud, F; Feltquate, DM; Galbraith, S; Goss, G; Jayson, GC; Jonker, DJ; Kantor, J; Kollia, G; McArthur, GA; Mokliatchouk, O; Nuyten, DSA; Rosen, LS; Rustin, G; Sawyer, MB; Sweeney, CJ; Syed, S; Velasquez, L; Wilding, G, 2011
)
0.37
" Throughout both phases, subjects were evaluated for adverse events (AEs) and best clinical response."( Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Chemidlin, J; Fischer, B; Hurwitz, H; Kollia, G; LoRusso, P; Masson, E; Pilat, MJ; Shapiro, GI; Syed, S, 2011
)
0.37
" Assessments included adverse events, PK, tumour response, 2[18F]fluoro-2-deoxyglucose positron-emitting tomography and K-Ras mutation analyses."( Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Buter, J; Chemidlin, J; El-Khoueiry, A; Feltquate, D; Ford, S; Galbraith, S; Garrett, CR; Hayes, W; Kollia, G; LoRusso, P; Major, P; Marshall, J; Mokliatchouk, O; Nuyten, DS; Rocha-Lima, CM; Siu, LL; Syed, S; Velasquez, L, 2011
)
0.37
" In addition, the pigments chlorophyll a and chlorophyll b, antioxidant enzyme activities catalase (CAT) and superoxide dismutase (SOD) as well as lipid peroxide malondialdehyde (MDA) were determined to evaluate the different toxic effects."( Enantioselective toxic effects and biodegradation of benalaxyl in Scenedesmus obliquus.
Diao, J; Huang, L; Lu, D; Zhou, Z, 2012
)
0.38
" of polyvinylpyrrolidone 10000 and 25000), C60-NO2-proline and C60-alanine had no toxic effect on HEp-2 cells."( [Study of cytotoxicity of fullerene C60 derivatives].
Bobylëv, AG; Bobylëva, LG; Fadeev, RS; Fadeeva, IS; Okuneva, AD; Poddubnaia, ZA; Salmov, NN,
)
0.13
" A comparison of the MERA with the conventional isobologram and the extended toxic unit summation revealed that the MERA characterizes the degree of toxicity interaction in the view of effect, with less limitation by different concentration ratios or effect levels."( [Characterizing the toxicity interaction of the binary mixture between DMSO and pesticide by the multi-effect residual analysis (MERA)].
Huo, XC; Liu, SS; Zhang, J, 2013
)
0.39
" Cell cytotoxicity and reactive oxygen species (ROS) changes were performed in combinations of As(III) and selenomethionine (SeMet) toxic mixes on, HEK293, human kidney cells."( Selenium mediated arsenic toxicity modifies cytotoxicity, reactive oxygen species and phosphorylated proteins.
Caruso, JA; Chitta, KR; Landero Figueroa, JA; Merino, EJ, 2013
)
0.39
" The most pronounced and selective toxic action of MET and products of its photodegradation was observed in the hepatic cell line."( Toxicity assessment of metoprolol and its photodegradation mixtures obtained by using different type of TiO2 catalysts in the mammalian cell lines.
Abramović, BF; Armaković, SJ; Četojević-Simin, DD; Šojić, DV, 2013
)
0.39
"Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is primarily limited by renal and gastrointestinal adverse effects."( Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats.
Bullins, KW; Denham, JW; Hanley, AV; Hanley, GA; Harirforoosh, S; Panus, PC; Wood, RC; Wyatt, JE, 2013
)
0.39
" Mice treated with PGW5 (25 and 50mg/kg/d) for 28 days did not show toxic effects in terms of weight gain and blood-chemistry analysis."( A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014
)
0.4
"PGW5 is a novel and safe antipsychotic, efficacious against schizophrenia-like positive and negative symptoms at nonsedative doses."( A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014
)
0.4
" The most commonly observed adverse events were headache, nausea and flatulence, which occurred similarly across the three groups."( Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A, 2014
)
0.4
"Interpreting Alzheimer's disease (AD) clinical trial (CT) outcomes is complicated by treatment dropouts and adverse events (AEs)."( Adverse events and dropouts in Alzheimer's disease studies: what can we learn?
Henley, DB; Schneider, LS; Sethuraman, G; Sundell, KL, 2015
)
0.42
" Overall annualized rates for discontinuations, discontinuations due to AEs, serious adverse events (SAEs), and deaths were 21."( Adverse events and dropouts in Alzheimer's disease studies: what can we learn?
Henley, DB; Schneider, LS; Sethuraman, G; Sundell, KL, 2015
)
0.42
" Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients."( Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.
Bam, RA; Cihlar, T; Yant, SR, 2014
)
0.4
" No serious adverse events were observed in either group."( Efficacy and safety of proton pump inhibitors (PPIs) plus rebamipide for endoscopic submucosal dissection-induced ulcers: a meta-analysis.
Cao, Z; Dong, W; Guo, X; Liu, M; Song, J; Wang, J; Ye, C; Yu, S; Zhang, J, 2014
)
0.4
" Treatment-emergent adverse events (TEAEs) are reported by body system along with pertinent laboratory, vital sign, and ECG findings."( Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
Dowsett, SA; Henley, DB; May, PC; Sethuraman, G; Sundell, KL, 2014
)
0.4
"Semagacestat treatment was associated with increased reporting of suspected Notch-related adverse events (gastrointestinal, infection, and skin cancer related)."( Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
Dowsett, SA; Henley, DB; May, PC; Sethuraman, G; Sundell, KL, 2014
)
0.4
" When the possibility of poor compliance and the potential adverse effects of misoprostol are considered, rebamipide appears to be a clinically effective and safe alternative."( Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity.
Cho, CS; Kang, YM; Kim, JH; Kim, SK; Lee, DH; Lee, SK; Lee, ST; Lee, YC; Park, SH; Park, W; Park, YW; Rew, JS; Yoo, WH, 2014
)
0.4
" No serious adverse events were observed in any of the patients in either group."( Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, m
Azuma, T; Higuchi, K; Iguchi, M; Machida, H; Morita, Y; Naito, Y; Takeuchi, T; Takeuchi, Y; Tamada, T; Tominaga, K; Uedo, N; Yagi, N; Yamao, J; Yazumi, S, 2015
)
0.42
" Serious adverse events were not observed in either group."( Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, m
Azuma, T; Higuchi, K; Iguchi, M; Machida, H; Morita, Y; Naito, Y; Takeuchi, T; Takeuchi, Y; Tamada, T; Tominaga, K; Uedo, N; Yagi, N; Yamao, J; Yazumi, S, 2015
)
0.42
" Taken together, potent MDR-modulating activity along with intracellular conversion into the natural flavonoid quercetin warrants development of the quercetin-amino acid conjugates as safe MDR modulators."( Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance.
Chong, Y; Choo, H; Kim, MK, 2014
)
0.4
" No subject experienced an adverse event that was serious or severe (grade 3/4)."( Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015
)
0.42
"Tenofovir alafenamide was safe and well tolerated; declines in HBV DNA were similar to tenofovir disoproxil fumarate at all doses evaluated."( Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015
)
0.42
" These results indicate that dietary supplementation with L-arginine (up to 630 mg/kg body weight/day) is safe in pigs for at least 91 days."( Safety of long-term dietary supplementation with L-arginine in pigs.
Hu, S; Li, X; McNeal, CJ; Meininger, CJ; Rezaei, R; Wu, G, 2015
)
0.42
" However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects; the novel prodrug tenofovir alafenamide achieves 90% lower plasma tenofovir concentrations."( Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016
)
0.43
" Seven patients in the tenofovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to adverse events."( Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016
)
0.43
" There were no discontinuations due to adverse events."( Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M, 2016
)
0.43
"Enantiomers of chiral compounds often exhibit enantioselective adverse effects and biochemical processes in non-target organisms."( Enantioselective metabolism and toxic effects of metalaxyl on primary hepatocytes from rat.
Qiu, J; Wang, X; Wang, Y; Zhang, P; Zhou, Z; Zhu, W, 2016
)
0.43
" We found that S421 phosphorylation mitigates neurodegeneration by increasing proteasome-dependent turnover of mHTT and reducing the presence of a toxic mHTT conformer."( Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
Daub, AC; Finkbeiner, S; Gu, X; Humbert, S; Kratter, IH; Lau, A; Masliah, E; Osmand, A; Saudou, F; Steffan, JS; Tsvetkov, AS; Weiberth, KF; Yang, XW; Zahed, H, 2016
)
0.43
"TAF has a similar tolerability, safety, and effectiveness to TDF and probably less adverse events related to renal and bone density outcomes in the treatment of naive and experienced patients with HIV-1."( The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
Lu, X; Wang, H; Xu, N; Yang, X, 2016
)
0.43
" The regimen was well tolerated and no discontinuations related to adverse events occurred."( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016
)
0.43
" Adverse events caused the premature study discontinuation of 12 individuals (4."( Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH, 2017
)
0.46
" The most frequently reported adverse event was dyskinesia (in 40 [14."( Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH, 2017
)
0.46
"Neonicotinoid residues can be present in soybean vegetative tissue, prey insects, and flower tissues, possibly making them toxic to pollinators and natural enemies."( Thiamethoxam Toxicity and Effects on Consumption Behavior in Orius insidiosus (Hemiptera: Anthocoridae) on Soybean.
Camargo, C; Giesler, LJ; Hunt, TE; Siegfried, BD, 2017
)
0.46
" The incidences of adverse events potentially related to the study drug were 16%, 26%, and 13% in the placebo, rebamipide 2%, and rebamipide 4% groups, respectively."( Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Beppu, T; Fujii, M; Fujii, T; Fujimoto, Y; Hasegawa, Y; Hirano, S; Iwae, S; Kojima, H; Matsushima, Y; Matsuura, K; Monden, N; Naka, Y; Nishimori, H; Ogawa, T; Okami, K; Ota, I; Sasaki, K; Tahara, M; Takahashi, S; Tanaka, K; Ueda, S; Ueda, T; Yokota, T, 2017
)
0.46
"The present phase II study suggests that mouth washing with rebamipide may be effective and safe for patients with HNC receiving chemoradiotherapy, and 4% liquid is the optimal dose of rebamipide."( Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Beppu, T; Fujii, M; Fujii, T; Fujimoto, Y; Hasegawa, Y; Hirano, S; Iwae, S; Kojima, H; Matsushima, Y; Matsuura, K; Monden, N; Naka, Y; Nishimori, H; Ogawa, T; Okami, K; Ota, I; Sasaki, K; Tahara, M; Takahashi, S; Tanaka, K; Ueda, S; Ueda, T; Yokota, T, 2017
)
0.46
" Response assessment and adverse event (AE) evaluation were performed every 21 days via VCOG criteria."( Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.
Burgess, KE; Clifford, CA; Fan, TM; Morges, MA; Phillips, B; Saba, CF; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2018
)
0.48
" Here, we show in the model system Caenorhabditis elegans that expression of the arginine-containing dipeptides, but not alanine-containing dipeptides, produces toxic phenotypes in multiple cellular contexts, including motor neurons."( Nuclear localized C9orf72-associated arginine-containing dipeptides exhibit age-dependent toxicity in C. elegans.
Lamitina, ST; Monaghan, J; Pandey, UB; Rudich, P; Snoznik, C; Watkins, SC, 2017
)
0.46
" Our discovery of canagliflozin-mediated simultaneous inhibition of GDH and ETC complex I in renal cells at clinically relevant concentrations, and their particular susceptibility to necrotic cell death during proliferation, provides a mechanistic rationale for the adverse effects observed especially in patients with preexisting chronic kidney disease or previous kidney injury characterized by sustained regenerative tubular epithelial cell proliferation."( Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.
Beneke, S; Delp, J; Dietrich, DR; Gutbier, S; Leist, M; Schlichenmaier, N; Secker, PF, 2018
)
0.48
" The overall incidence and severity of adverse events was similar between groups, although headache occurred more frequently in the bictegravir group than in the boosted protease inhibitor group."( Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018
)
0.48
"Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in adults with HIV-1 infection."( Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018
)
0.48
" In total, 300 adverse events were classified as related to safinamide in 132 patients (44."( [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J, 2018
)
0.48
"Concerns have increased about the risk of fatal adverse events (FAEs) associated with molecular targeted agents (MTAs) in the treatment of advanced hepatocellular carcinoma (HCC)."( Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Hu, Y; Li, X; Lou, L; Tu, J; Wan, J; Wu, S; Wu, Z, 2018
)
0.48
" Adverse events were recorded by patients in specially developed diaries."( Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.
Andreev, DN; Dicheva, DT; Maev, IV; Partzvania-Vinogradova, EV; Samsonov, AA, 2018
)
0.48
" The incidence of adverse events between the groups was comparable: 22."( Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.
Andreev, DN; Dicheva, DT; Maev, IV; Partzvania-Vinogradova, EV; Samsonov, AA, 2018
)
0.48
"We pooled clinical renal safety data across 26 treatment-naive and antiretroviral switch studies to compare the incidence of proximal renal tubulopathy and discontinuation due to renal adverse events between participants taking TAF-containing regimens vs."( Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L, 2019
)
0.51
"001) discontinued due to a renal adverse event."( Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L, 2019
)
0.51
" The biological and physicochemical properties of nanoparticles bring new challenges with regards to management of potential adverse health effects following exposure."( Synthesis, characterization and cytotoxicity of alanine-capped CuS nanoparticles using human cervical carcinoma HeLa cells.
Mofokeng, TP; Moloto, MJ; Shumbula, PM; Tetyana, P, 2019
)
0.51
" Few discontinued due to adverse events (2% D/C/F/TAF arm)."( Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E, 2019
)
0.51
" Drug-related grade ≥2 adverse events and withdrawals due to adverse events occurred in 17 (4."( Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B, 2020
)
0.56
" CAT tail aggregation has been hypothesized to either protect cells by sequestering potentially toxic incomplete polypeptides or harm cells by disrupting protein homeostasis."( Aggregation of CAT tails blocks their degradation and causes proteotoxicity in S. cerevisiae.
Brandman, O; Giafaglione, JM; Park, JH; Sitron, CS, 2020
)
0.56
" Both treatments were safe and well-tolerated, and most adverse events were similar as mild to moderate in severity."( Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Chen, Y; Lu, Y; Tao, X; Zhang, L; Zhou, Y, 2020
)
0.56
" Response assessment and adverse event (Ae) evaluation were performed every 21 days via Veterinary Cooperative Oncology Group (VCOG) criteria."( Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z, 2020
)
0.56
" Adverse events occurred in 58."( Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020
)
0.56
" All adverse events were grade 1 or 2 in severity."( Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
Cao, H; Chng, E; German, P; Humeniuk, R; Ling, J; Mathias, A; Osinusi, A; Shen, G; Vu, A, 2020
)
0.56
" Adverse events (AEs) occurred in 78."( Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020
)
0.56
" Adverse events occurred in 30% of patients and led to drug discontinuation in 11% of cases."( The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Alborghetti, M; Bianchini, E; Galli, S; Giovannelli, M; Pontieri, FE; Rinaldi, D; Salvetti, M; Sforza, M, 2021
)
0.62
" These findings provide reassurance that the combination of TAF, boosted PIs and ledipasvir/sofosbuvir is safe in HIV/HCV-coinfected populations."( Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020
)
0.56
" pertussis B1917 on mammalian HeLa cells and expression of Bp BteAΔA503 was highly toxic to Saccharomyces cerevisiae cells."( Cytotoxicity of the effector protein BteA was attenuated in Bordetella pertussis by insertion of an alanine residue.
Bayram, J; Holubova, J; Jurnecka, D; Kamanova, J; Kucera, J; Malcova, I; Sebo, P; Sedlacek, R; Sinkovec, L; Streparola, G, 2020
)
0.56
" Secondary assessments included maternal HBV DNA reduction at delivery, and maternal or infant adverse events during follow up."( Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020
)
0.56
" No severe adverse effects were reported in either mothers or infants."( Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020
)
0.56
"To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials."( Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Ader, F, 2020
)
0.56
"The results of the present study confirm that the overnight switch from rasagiline to safinamide is safe and well tolerated by patients."( Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M, 2021
)
0.62
"To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions."( A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T, 2021
)
0.62
"8% patients experienced adverse events, 27."( A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T, 2021
)
0.62
" Remdesivir reduced serious adverse effects by absolute 6% and no significant Grade 3 or 4 adverse effects were reported."( Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.
Abdallah, MS; Elsawah, HK; ElShafie, AH; Elsokary, MA, 2021
)
0.62
" Because TDF can lead to renal impairment and a decrease in bone mineral density (BMD), the prodrug tenofovir alafenamide (TAF) may be considered a viable alternative with fewer adverse effects."( Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K, 2021
)
0.62
" After 1 year, 22 patients were still taking TAF; two patients had been lost to follow-up; one patient had died; and four patients had discontinued therapy because of TAF-related adverse effects."( Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K, 2021
)
0.62
" The most common adverse reaction was hepatic impairment, although the trials reported a similar proportion of adverse events in the intervention and control groups."( Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review.
Andersson, N; Cockcroft, A; Laurie, C; Pimentel, J, 2021
)
0.62
" Trial data report a similar proportion of adverse events in treated and control groups."( Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review.
Andersson, N; Cockcroft, A; Laurie, C; Pimentel, J, 2021
)
0.62
"6%) patients because of adverse effects."( Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ, 2021
)
0.62
" Harms are typically assessed through the collection of adverse events (AEs)."( Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
Cornelius, V; Cro, S; Phillips, R, 2020
)
0.56
" The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events."( Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
An, MH; Hwang, TH; Kim, MS; Kim, WJ, 2020
)
0.56
" Meanwhile, the toxic effects were also evaluated by comparing the different influences of these two compounds on related physiological indicators, and functional enzyme activities."( The different toxic effects of metalaxyl and metalaxyl-M on Tubifex tubifex.
Guo, HM; Liu, X; Lu, ZH; OuYang, MN; Yang, ZH; Zhou, DD, 2021
)
0.62
" No drug-related adverse events were observed within a 48-week observation period."( The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X, 2021
)
0.62
"Pesticides have adverse effects on the cellular functionality, which may trigger myriad of health consequences."( Cytotoxicity and genotoxicity of methomyl, carbaryl, metalaxyl, and pendimethalin in human umbilical vein endothelial cells.
Al-Khedhairy, AA; Alwathnani, HA; Ansari, SM; Musarrat, J; Saquib, Q; Siddiqui, MA, 2021
)
0.62
"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2."( The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M, 2021
)
0.62
" magna assay revealed toxic effects of BMAA."( Presence of ß-N-methylamino-L-alanine in cyanobacteria and aquatic organisms from waters of Northern Poland; BMAA toxicity studies.
Błaszczyk, A; Mazur-Marzec, H; Siedlecka-Kroplewska, K; Woźniak, M, 2021
)
0.62
" The scientific community is studying and testing numerous compounds that can be effective and safe for treating people with covid-19."( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021
)
0.62
" No differences for the risk of any adverse events are observed between convalescent plasma and remdesivir compared to standard treatment."( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021
)
0.62
" Furthermore, no significant association was observed between remdesivir treatment and an increased risk of adverse events."( Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.
Chen, CH; Chen, KH; Hsueh, PR; Lai, CC; Wang, CY; Wang, YH, 2021
)
0.62
" Primary safety outcomes, compared pairwise among treatment groups, were the occurrence of a composite adverse pregnancy outcome (ie, either preterm delivery, the infant being born small for gestational age, stillbirth, or spontaneous abortion) in all participants with a pregnancy outcome, and the occurrence of grade 3 or higher maternal and infant adverse events in all randomised participants."( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021
)
0.62
" Significantly fewer participants in the dolutegravir, emtricitabine, and tenofovir alafenamide fumarate group (52 [24%] of 216) had a composite adverse pregnancy outcome than those in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group (70 [33%] of 213; estimated difference -8·8% [95% CI -17·3 to -0·3], p=0·043) or the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (69 [33%] of 211; -8·6% [-17·1 to -0·1], p=0·047)."( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021
)
0.62
" The dolutegravir, emtricitabine, and tenofovir alafenamide fumarate regimen had the lowest frequency of composite adverse pregnancy outcomes and of neonatal deaths."( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021
)
0.62
" No liver function derangements or any other major adverse events with the drug were reported."( Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.
Banerjee, S; Chauhan, S; Desai, S; Kute, VB; Meshram, HS; Mishra, V; Navadiya, V; Patel, H; Rizvi, SJ, 2021
)
0.62
"RDV therapy is safe and clinically feasible in renal transplant recipients as seen in our cohort."( Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.
Banerjee, S; Chauhan, S; Desai, S; Kute, VB; Meshram, HS; Mishra, V; Navadiya, V; Patel, H; Rizvi, SJ, 2021
)
0.62
" To exclude toxic concentrations of potential drugs, the network was expanded to include a toxic score (TOX) that detected cell death (CPETOXnet)."( Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.
Bhatia, S; Borkhardt, A; Kather, JN; Kronberg, RM; Lang, KS; Lang, PA; Müller, L; Ostermann, PN; Pandyra, AA; Schaal, H; Stachura, P; Werner, J, 2021
)
0.62
" Adverse events were reported in 8 (7%) patients."( [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J, 2021
)
0.62
" However, we found a large difference between the high percentages of patients reporting an adverse event in three phase 3 clinical trials and our results."( [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J, 2021
)
0.62
" The outcomes studied were mortality, all adverse events, serious adverse events, and clinical improvement."( Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Goudarzi, R; Mehrolhassani, MH; Tasavon Gholamhoseini, M; Yazdi-Feyzabadi, V, 2021
)
0.62
"Remdesivir has positive effects on clinical improvement, and reduction of the risk of serious adverse events."( Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Goudarzi, R; Mehrolhassani, MH; Tasavon Gholamhoseini, M; Yazdi-Feyzabadi, V, 2021
)
0.62
" TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks."( Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022
)
0.72
" The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported."( Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021
)
0.62
"Primary outcome was mortality and secondary outcomes were time to clinical improvement and safety outcomes like serious adverse events, respiratory failure."( Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis.
Chugh, A; Chugh, VK; Khera, D; Khera, PS; Singh, S, 2021
)
0.62
" Significant decrease was found in the risk of serious adverse events (RR=0."( Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis.
Chugh, A; Chugh, VK; Khera, D; Khera, PS; Singh, S, 2021
)
0.62
" In rats, systemic and local findings were considered not adverse due to their low severity and reversibility; therefore, the "no observed adverse effect level" (NOAEL) was set at 1,000 μg/kg/day."( A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D, 2021
)
0.62
"Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men."( Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D, 2021
)
0.62
" The Adverse events [AEs], Serious adverse events [SAEs] and Treatment Discontinuation due to Adverse Events (TDAE) were used as primary outcome measures."( A Meta-Analysis of Safety of Different Regimens of Remdesivir in COVID-19 Patients.
Bose, D; Konwar, M; Maurya, M, 2022
)
0.72
" Serious adverse effects (SAEs) were significantly less common in patients treated with remdesivir, with an absolute risk difference of 6% (RD -0."( Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis.
Angamo, MT; Mohammed, MA; Peterson, GM, 2022
)
0.72
" The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups."( Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Adams, DH; Alatorre-Alexander, J; Cardoso, A; Chakladar, S; Crowe, B; de Bono, S; de Cassia Pellegrini, R; Ely, EW; Estrada, V; Goldman, JD; Kartman, CE; Krishnan, V; Liao, R; Marconi, VC; Piruzeli, MLB; Ramanan, AV; Reis, P; Som, M; Zhang, X, 2021
)
0.62
" Week 48 virologic suppression (HIV-1 RNA <50 copies/mL), resistance, adverse events (AEs), and laboratory parameters were assessed."( Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K, 2021
)
0.62
"In individuals with a history of PRT on TDF, 96 weeks of TAF was not associated with recurrent PRT or adverse effects on renal tubular function, bone turnover, or BMD."( Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A, 2021
)
0.62
" Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1-2) and led to 8 discontinuations."( Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
Cruz, D; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP, 2021
)
0.62
"Safinamide was well tolerated as a treatment for PD, and there was no significant difference in the frequency and severity of adverse events between the safinamide and placebo groups."( Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y, 2022
)
0.72
" We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO)."( Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
Abou Ghayda, R; Ban, K; Cargnin, S; Choi, JY; Choi, SW; Chung, SK; Dragioti, E; Go, YY; Hong, SH; Jacob, L; Jung, JW; Jung, SY; Kim, AY; Kim, MS; Kim, NK; Kostev, K; Koyanagi, A; Kronbichler, A; Lee, KH; Lee, SW; Li, H; Moon, SH; Park, SJ; Salem, JE; Shin, JI; Shin, JS; Smith, L; Solmi, M; Terrazzino, S; Tizaoui, K; Yon, DK, 2022
)
0.72
"ETV, TDF, and TAF were safe antiviral agents and showed similar antiviral effect for CHB at 48 weeks."( Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong, S; Kim, HI; Shin, HP, 2022
)
0.72
" We evaluated the safety of remdesivir by examining the incidence of discontinuation of remdesivir treatment because of adverse events and the incidence of any adverse events."( Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19).
Esaka, N; Fujita, K; Hata, H; Kanai, O; Mio, T; Nanba, K; Odagaki, T; Seta, K; Yasoda, A, 2021
)
0.62
" Discontinuation of remdesivir because of adverse events occurred in one older patient (3."( Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19).
Esaka, N; Fujita, K; Hata, H; Kanai, O; Mio, T; Nanba, K; Odagaki, T; Seta, K; Yasoda, A, 2021
)
0.62
" While aggregated proteins that are responsible for the pathogenesis of neurodegenerative disorders show cell-to-cell propagation and thereby exert toxic effects on the recipient cells, whether this is also the case with expanded PA has not been studied."( Toxicity of internalized polyalanine to cells depends on aggregation.
Hayashi, F; Iizuka, Y; Kawasaki, T; Nakamura, K; Owada, R; Sonoyama, M, 2021
)
0.62
"Although remdesivir (GS-5734) has recently demonstrated clinical benefits against the pandemic outbreak of coronavirus disease 2019 (COVID-19), neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings."( Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Dragioti, E; Jacob, L; Jung, SY; Kang, HC; Kim, JH; Kim, MS; Kostev, K; Koyanagi, A; Lascu, A; Lee, S; Lee, SW; Salem, JE; Shin, JI; Smith, L; Tizaoui, K; Yang, JW; Yon, DK, 2021
)
0.62
"Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting."( Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Dragioti, E; Jacob, L; Jung, SY; Kang, HC; Kim, JH; Kim, MS; Kostev, K; Koyanagi, A; Lascu, A; Lee, S; Lee, SW; Salem, JE; Shin, JI; Smith, L; Tizaoui, K; Yang, JW; Yon, DK, 2021
)
0.62
" Remdesivir was overall well tolerated, and total 119 adverse events were reported; most common were nausea and vomiting in 45."( Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database.
Gogtay, J; Gupte, V; Hegde, R; Jadhav, S; Kalathingal, K; Malabade, R; Sawant, S, 2022
)
0.72
" Drug-related adverse events were more frequent with DTG/3TC (15%; leading to discontinuation in 4%) than TAF-based regimens (5%; leading to discontinuation in 1%) through week 144, but rates were comparable after week 48 (4%; leading to discontinuation in 1% in both groups)."( Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B, 2022
)
0.72
"To summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19."( Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D, 2022
)
0.72
" For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty."( Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D, 2022
)
0.72
" This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER (treatment-naïve) and EMERALD (virologically suppressed) studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg."( Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.
Anderson, D; Baugh, B; Bejou, N; Campbell, J; Dunn, K; Luo, D; Seyedkazemi, S,
)
0.13
"We aimed to assess longitudinal changes in clinical indexes of corona disease 2019 (Covid-19) patients with mild pulmonary infection during 5 days of remdesivir therapy and determine the effect of age and gender on remdesivir adverse effects (AE)."( Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.
Amanollahi, A; Basir Ghafouri, H; Hoseini, SE; Moradi Moghaddam, O; Sedighi, M; Tavakoli, N, 2022
)
0.72
"This study aimed to detect safety signals of rebamipide and search for adverse events (AEs) of rebamipide that are more common than those of other drugs for peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) in the elderly population."( Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.
Jang, E; Jeong, JE; Kim, MG; Lee, JY; Park, M, 2022
)
0.72
" Consistent with previous findings, we observed adverse local toxicity and necrosis near the tenofovir alafenamide implant site."( Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A, 2022
)
0.72
" In view of the adverse toxic effects of both on the mammalian liver, it is necessary to conduct a cumulative risk assessment of their dietary exposure to consumers."( Dissipation and Residue of Metalaxyl-M and Azoxystrobin in Scallions and Cumulative Risk Assessment of Dietary Exposure to Hepatotoxicity.
Chai, Y; Du, X; Liu, R; Yuan, L, 2022
)
0.72
"To evaluate the cumulative incidence (CI) of suspected adverse drug reactions (ADR) from TCZ in adult patients with COVID-19."( [Surveillance of adverse effects of Tocilizumab for COVID-19].
Fuenzalida, T; González, A; Gutiérrez, W; Iturra, P; Severino, N, 2022
)
0.72
" Non-infectious ADRs were categorized according to the Common Terminology Criteria for Adverse Events and the development of infection was classified as present or absent."( [Surveillance of adverse effects of Tocilizumab for COVID-19].
Fuenzalida, T; González, A; Gutiérrez, W; Iturra, P; Severino, N, 2022
)
0.72
" A rise in alanine and aspartate aminotransferases and the development of infections were the most frequent adverse events."( [Surveillance of adverse effects of Tocilizumab for COVID-19].
Fuenzalida, T; González, A; Gutiérrez, W; Iturra, P; Severino, N, 2022
)
0.72
" All patients recovered without any sequelae, and no serious adverse events were reported."( Safety of Remdesivir in 20 Children with COVID-19-Case Series-
Jinda, T; Kasai, M; Manabe, S; Mizuno, S, 2022
)
0.72
" Safety was assessed by treatment-emergent adverse events (TEAEs)."( A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N, 2023
)
0.91
" The inserts were safe and highly acceptable."( A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N, 2023
)
0.91
" The most common adverse events included nausea, dizziness, and cough."( Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.
Anoshchenko, O; Chen, S; Davies, S; DeZure, A; Dresser, M; Ellis, S; Girish, S; Humeniuk, R; Johnston, M; Juneja, K; Llewellyn, J; Osinusi, A; Palaparthy, R; Share, A; Winter, H; Xiao, D, 2023
)
0.91
"Remdesivir is an antiviral agent, which was shown to be safe and effective in treating early COVID-19, but its favourable impact in hospitalised patients with non-critical disease is still under investigation."( Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency.
Adinolfi, A; Bernasconi, DP; Bertuzzi, M; Colombo, F; Del Gaudio, F; Dicuonzo, A; Epis, OM; Giannattasio, C; Maloberti, A; Rossetti, C; Scaglione, F; Tarsia, P; Travi, G; Ughi, N; Valsecchi, MG, 2023
)
0.91
"5%) patients stopped the treatment due to adverse reactions."( Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency.
Adinolfi, A; Bernasconi, DP; Bertuzzi, M; Colombo, F; Del Gaudio, F; Dicuonzo, A; Epis, OM; Giannattasio, C; Maloberti, A; Rossetti, C; Scaglione, F; Tarsia, P; Travi, G; Ughi, N; Valsecchi, MG, 2023
)
0.91
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."( Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023
)
0.91
"Long-term administration of TDF has resulted in stronger adverse effects than TAF and ETV in regard to both renal function and bone tissue in CHB patients."( Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" In control rats, the volume of distribution (Vss), metabolic clearance rate (MCR), and distribution half-life (distribution t1/2) of urodilatin in plasma were not significantly different from those of ANF."( Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition.
Abassi, ZA; Hunsberger, S; Keiser, HR; Klein, H; Tate, J; Trachewsky, D, 1992
)
0.28
" However, there is only little knowledge about the pharmacokinetic behavior of this new group of anticancer agents."( A new comprehensive technique of catheterisation, blood sampling, sample preparation and sample analysis by means of high-pressure liquid chromatography for pharmacokinetic studies with estradiol-linked nitrosoureas and their metabolites.
Berger, MR; Betsch, B; Spiegelhalder, B, 1990
)
0.28
" The higher antineoplastic activity of the hormone-linked drug can mainly be attributed to differences in the pharmacokinetic behaviour."( New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities?
Berger, MR; Betsch, B; Eisenbrand, G; Schmähl, D; Spiegelhalder, B, 1989
)
0.28
" At plasma concentrations below 10 micrograms/ml, elimination was monoexponential with a half-life of 32 +/- 11 min (mean +/- SD)."( Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans.
Moore, GW; Oates, JA; Rabin, D; Stacpoole, PW; Wells, PG; Wilkinson, GR, 1980
)
0.26
" The constants of absorption from peritoneal cavity (Ka) and elimination from plasma (Ke) and the serum absolute bioavailability (BA(a)) after 8 h were calculated assuming a bicompartment pharmacokinetic model."( A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications.
Mahedero, G; Mariñõ, E; Morán, JM; Ribeiro, JM; Salas, J; Vinagre, LM,
)
0.13
" Dengue patients manifested the same pharmacokinetic responses to a 20 g Ala-Gln bolus as healthy controls."( The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever.
Fürst, P; Klassen, P; Mazariegos, M; Solomons, NW, 2000
)
0.31
" The Fab' fragment of the antibody was therefore modified with polyethylene glycol (PEG) in order to obtain a more desirable pharmacokinetic profile."( Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
Chen, H; Chuntharapai, A; DeForge, L; Deveney, J; Fan, A; Galan, W; Gonzalez, T; Gribling, P; Hale, V; Hébert, C; Hsei, V; Kim, KJ; Koumenis, I; Lee, WP; Leong, SR; McKay, P; Narindray, D; Presta, L; Reichert, M; Schoenhoff, M; Shahrokh, Z; Snedecor, B; Tumas, DB; Wagner, B; Zapata, G, 2001
)
0.31
" Roxifiban has pharmacokinetic and pharmacodynamic properties believed to be more favorable than the earlier oral agents."( Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Billheimer, JT; He, B; Seiffert, D; Spitz, SM; Stern, AM, 2002
)
0.31
" The differential time courses in the three compartments do not seem to be due to pharmacokinetic factors."( Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]az
Adams, WJ; Hosley, JD; Lanz, TA; Merchant, KM, 2004
)
0.32
" In single dose trials blood sampling covered a 24 h-period in pharmacodynamic trials, 48 h-period in pharmacokinetic trials."( Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Caccia, C; Cattaneo, C; Crivelli, F; Dal Bo, L; Fariello, RG; Ismaili, S; Marzo, A; Monti, NC, 2004
)
0.32
" After comparing the pharmacokinetic behavior of panipenem in patients with ESRD and that of a surrogate marker of efficacy, we recommend that these patients be treated with 500 mg/500 mg of panipenem/betamipron once daily, which gives a similar clinical result in a patient with normal renal function."( Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005
)
0.33
"Population pharmacokinetic analyses were performed with plasma concentrations from 26 healthy volunteers and 41 patients."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
" The method was successfully applied to pharmacokinetic studies of BX enantiomers in rabbits."( Stereoselective determination of benalaxyl in plasma by chiral high-performance liquid chromatography with diode array detector and application to pharmacokinetic study in rabbits.
Jia, G; Qiu, J; Wang, Q; Wang, X; Zhou, Z; Zhu, W, 2007
)
0.34
" The current data describe the pharmacokinetic behavior of LY544344 and LY354740, with a specific focus on the first-pass activation processes and dose linearity in rats and dogs."( Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass
Abraham, T; Perkins, EJ, 2007
)
0.34
" Human efficacious dose was predicted based on projected human pharmacokinetic parameters and exposure at efficacious doses in the mouse efficacy models."( Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Bhide, R; D'Arienzo, C; Fargnoli, J; Kamath, AV; Marathe, PH; Zhang, Y, 2009
)
0.35
" Pharmacokinetic parameters were determined using a noncompartmental method."( Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
Cho, HY; Lee, YB; Park, GK; Yoon, H, 2009
)
0.35
" No significant sequence, subject, formulation, or period effects were detected for any pharmacokinetic parameter."( Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
Cho, HY; Lee, YB; Park, GK; Yoon, H, 2009
)
0.35
" There was no evidence that rebamipide pharmacokinetic parameters were influenced by genetic polymorphisms in the ABCB1 gene (exons 21 and 26)."( Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
Cho, HY; Lee, YB; Park, GK; Yoon, H, 2009
)
0.35
" The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma concentration was 6146 ng/ml, mean terminal half-life was 13."( Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Fischer, BS; Gan, J; Ganapathi, R; Gong, J; Iyer, R; Masson, E; Mekhail, T; Patricia, D; Pursley, J; Williams, D, 2010
)
0.36
"The purpose of this analysis was to develop a population pharmacokinetic model for CS-917, an oral hypoglycemic prodrug, and its 3 metabolites."( Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites.
Carrothers, TJ; Habtemariam, B; Kastrissios, H; Khariton, T; Kshirsagar, S; Mager, DE; Rohatagi, S; Walker, JR, 2012
)
0.38
" In Part A, subjects received a single dose of brivanib alaninate (800 mg) either in a fasting state or following ingestion of a high-fat meal (approximately 951 kcal [15% protein, 33% carbohydrate, 52% fat]); serial blood samples were collected for pharmacokinetic analysis up to 48 h post-dosing."( Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Chemidlin, J; Fischer, B; Hurwitz, H; Kollia, G; LoRusso, P; Masson, E; Pilat, MJ; Shapiro, GI; Syed, S, 2011
)
0.37
" The present study evaluated pharmacokinetic parameters and safety/tolerability upon coadministration of brivanib alaninate and midazolam."( Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Clemens, PL; Dhar, A; Kollia, G; Lathers, D; Masson, E; Syed, S; Walters, I, 2012
)
0.38
" We reasoned that an animal model would be suitable for GSI discovery if the pharmacokinetic (PK)/pharmacodynamic (PD) relationship of a compound for Aβ lowering in this model is predictive of that in human."( Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Atchison, K; Becker, SL; Efremov, I; Hallgren, AJ; Lu, Y; Miller, EH; Nolan, CE; Osgood, SM; Pustilnik, LR; Riddell, D; Robshaw, AE; Stepan, AF; Subramanyam, C; Zhang, L, 2011
)
0.37
"This study was conducted primarily to improve the solubility of rebamipide, a poorly water-soluble anti-ulcer drug, using novel ternary solid dispersion (SD) systems and secondly to evaluate the effect of solubility enhancement on its pharmacokinetic (PK) and pharmacodynamic (PD) profile."( Physicochemical, pharmacokinetic and pharmacodynamic evaluations of novel ternary solid dispersion of rebamipide with poloxamer 407.
Chi, SC; Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Tung, NT, 2013
)
0.39
" Serial blood samples were collected over 240 h post dose to quantify safinamide parent drug and metabolite concentrations for pharmacokinetic evaluation."( Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
Fauchoux, N; Gallemann, D; Hermann, R; Johne, A; Krösser, S; Marquet, A; Wolna, P, 2012
)
0.38
" In this study, we investigated the pharmacokinetic drug interactions of rebamipide with two selected NSAIDs, celecoxib or diclofenac."( Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats.
Cooper, DL; Harirforoosh, S; Wood, RC; Wyatt, JE, 2014
)
0.4
"Administration of 40 mg of tenofovir alafenamide for 14 days resulted in lower tenofovir Cmax (13 versus 207 ng/mL) and lower systemic exposures (AUC0-t, 383 versus 1810 ng · h/mL) compared with subjects who received tenofovir disoproxil fumarate."( Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A, 2014
)
0.4
"Between May 22, 2013, and July 22, 2014, we enrolled 50 participants, and all 50 received the assigned treatment; 24 participated in the intensive pharmacokinetic assessment."( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016
)
0.43
"The elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was well tolerated and achieved component plasma pharmacokinetic exposures similar to those in adults."( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016
)
0.43
"In this study, the population pharmacokinetic (PK) analysis of rebamipide (Reba) in healthy male Korean subjects was analyzed using the nonlinear mixed effects modeling method."( Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.
Cho, HY; Lee, YB; Ngo, L; Tran, P; Yoo, HD, 2017
)
0.46
"Bckground: One of the major challenges of biopharmaceuticals having short plasma half-life is that daily high dose injections are needed which can lead to economic burden, patient inconvenience and undesirable side effects."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018
)
0.48
"In this review, we focus on PASylation technology as a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018
)
0.48
"We explain the general concept of PASylation, its development; advantages compared to other PK modifying technologies and describe furthermore the pharmacodynamic (PD) and PK properties of several PAS-fusion proteins in preclinical studies."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018
)
0.48
"The biodegradable PAS sequence was already used for prolonging plasma half-life of clinical important agents such as antibody fragments, cytokines, enzymes and receptor-binding peptides."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018
)
0.48
"A single-arm, prospective, nonrandomized, cross-over, pharmacokinetic study in patients receiving a TDF-containing regimen (TDF 300 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg) switched to a TAF-containing FDC regimen (TAF 10 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg)."( Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Bares, SH; Dyavar, SR; Fletcher, CV; Havens, J; Lee, S; O'Neill, J; Podany, AT; Scarsi, KK; Swindells, S, 2018
)
0.48
" Population pharmacokinetic models were developed using measured intracellular metabolite, endogenous nucleotide competitors, and extracellular parent drug concentrations."( A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018
)
0.48
"AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile."( Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
Astruc, B; Beigelman, L; Berliba, E; Blatt, LM; Chanda, S; Fry, J; Kakuda, TN; Khorlin, N; McClure, MW; Patat, A; Streinu-Cercel, A; Tsertsvadze, T; Vijgen, L; Vuong, J; Westland, C; Zhang, Q, 2018
)
0.48
" coli-expressed recombinant fused and unfused proteins were compared in terms of bioactivity, physicochemical, and pharmacokinetic properties using standard methods."( Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology.
Aghaabdollahian, S; Ahangari Cohan, R; Asadi Karam, MR; Davami, F; Latif Dizaji, S; Moazzami, R; Norouzian, D; Torkashvand, F; Vaseghi, G, 2019
)
0.51
" Here, we describe and evaluate the conjugation of a single domain i-body, AD-114, which targets CXCR4, to a panel of half-life extension technologies including a human serum albumin-binding peptide, linear and branched PEG, and PASylation (PA600)."( Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4.
Binder, U; Darby, WG; Foley, M; Frigerio, M; Griffiths, K; Hosking, CG; Lloyd, P; Machacek, M; McDowell, W; Renaud, L; Skerra, A; Tommasi, R, 2019
)
0.51
" In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug-drug interactions (DDIs)."( Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Ceckova, M; Chen, S; Guo, L; Hofman, J; Kammerer, S; Küpper, JH; Sorf, A; Staud, F; Sucha, S; Vagiannis, D, 2019
)
0.51
" Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"For hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients."( Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Agrati, C; Ascoli Bartoli, T; Avataneo, V; Capobianchi, MR; Caputi, P; Castilletti, C; D'Avolio, A; Forini, O; Ippolito, G; Lalle, E; Marchioni, L; Nicastri, E; Notari, S; Scorzolini, L; Tempestilli, M, 2020
)
0.56
"Therapeutic fragmented antibodies show a poor pharmacokinetic profile that leads to frequent high-dose administration."( New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody.
Cohan, RA; Karami, E; Khodabakhsh, F; Khosravy, MS; Mehdizadeh, A; Salimian, M; Vafabakhsh, A, 2020
)
0.56
" Pharmacokinetic sampling, urine biomarker collection [urine protein (UPCR), retinol binding protein (RBP) and β2 microglobulin (β2M) normalized to creatinine] and safety assessments occurred at the end of each phase."( Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020
)
0.56
"Pregnant women receiving TAF 10 mg with cobicistat or TAF 25 mg without boosting as part of clinical care had intensive pharmacokinetic assessments performed during the second and third trimesters, and 6-12 weeks postpartum."( Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A, 2021
)
0.62
" Because measurement of such concentrations is unrealistic in patients, a physiologically-based pharmacokinetic (PBPK) model was developed to characterize RDV and TN disposition."( Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.
Gallo, JM, 2021
)
0.62
" This report summarizes development of a remdesivir physiologically-based pharmacokinetic (PBPK) model that accurately describes observed adult remdesivir and metabolites exposure and predicts pediatric remdesivir and metabolites exposure."( Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
German, P; Kirby, BJ; Lutz, JD; Mathias, A; Pikora, C; Reddy, S, 2021
)
0.62
" This phase I, open-label, 2-period, 1-way study assessed potential pharmacokinetic (PK) interactions between GSK3640254 and tenofovir alafenamide/emtricitabine (TAF/FTC; including the metabolite tenofovir [TFV]) in healthy volunteers."( A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E, 2021
)
0.62
" In spite of United States Food and Drug Administration's recent assent of remdesivir as the only approved agent for COVID-19, there is limited information available about the physicochemical, metabolism, transport, pharmacokinetic (PK), and drug-drug interaction (DDI) properties of this drug."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
0.62
" Physiologically based pharmacokinetic (PBPK) modeling of GastroPlus was used to simulate different patient populations based on age, weight, liver function, and renal function status."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
0.62
"This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B)."( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021
)
0.62
" Furthermore, this study will deliver pharmacokinetic datasets for remdesivir drug concentrations and demographic characteristics which could support pharmacometric approaches for simulation of remdesivir treatment regimens in patients concurrently using tenofovir/lamivudine and/or atazanavir/ritonavir."( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021
)
0.62
"Tenofovir alafenamide (TAF) is a key component of HIV treatment, but pharmacokinetic data supporting the use of TAF during pregnancy are limited."( Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022
)
0.72
" Intensive pharmacokinetic assessments were performed during the second and third trimesters and 6-12 weeks postpartum."( Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022
)
0.72
" TAF was only quantifiable in 2/25 maternal delivery samples and below the limit of quantification in all cord blood and infant washout samples, likely because of the short half-life of TAF."( Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022
)
0.72
" Non-compartmental analyses were performed to quantify the pharmacokinetic parameters."( Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022
)
0.72
"In this first pharmacokinetic study of TAF monotherapy in breastfeeding women with CHB, concentrations of TAF and TFV were low in breast milk with negligible infant exposure, supporting the use of TAF to prevent MTCT."( Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022
)
0.72
" A prospective observational pharmacokinetic study was performed in non-critically ill hospitalized COVID-19 patients with hypoxemia."( Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
Bosma, LBE; Leegwater, E; Moes, DJAR; Ottens, TH; van der Meer, IM; van Nieuwkoop, C; Wilms, EB, 2022
)
0.72
"To study the pharmacokinetic inter-individual variability of remdesivir and its main metabolite GS-441524 in a real-world setting of COVID-19 inpatients and to identify possible associations with different demographic/biochemical variables."( Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
Agrati, C; Ascoli Bartoli, T; Benvenuto, D; Marchioni, L; Nicastri, E; Stazi, GV; Tempestilli, M, 2022
)
0.72
" Linear regression, logistic regression and multiple linear regression tests were used for statistical comparisons of pharmacokinetic parameters and variables."( Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
Agrati, C; Ascoli Bartoli, T; Benvenuto, D; Marchioni, L; Nicastri, E; Stazi, GV; Tempestilli, M, 2022
)
0.72
" Model-based simulations revealed 294% and 515% increases of median tenofovir Cmin in patients with CLCR of 15-29 mL/min (CKD stage 3), and less than 15 mL/min (stage 4), respectively, compared with normal renal function (CLCR = 90-149 mL/min)."( Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P, 2023
)
0.91
"This randomized, parallel-group study evaluated the plasma pharmacokinetic profile of safinamide in 24 healthy Chinese men and women, randomly assigned to receive 50 or 100 mg of safinamide as a single dose, followed, after a 7-day washout, by multiple doses once daily for 7 days."( Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers.
Cattaneo, C; Jing, S; Leuratti, C; Vaja, V; Yuan, Y, 2023
)
0.91

Compound-Compound Interactions

Glycine or DL-alpha-alanine potentiated the chemotherapeutic action of 3,6-diaminoacridinium without increasing its toxicity. The in vitro activity of fludalanine combined with pentizidone was compared with the activities of ampicillin, ticarcillin, cefuroxime, ceftazidime, and trimethoprim.

ExcerptReferenceRelevance
"Glycine or DL-alpha-alanine potentiated the chemotherapeutic action of 3,6-diaminoacridinium without increasing its toxicity when these amino acids were combined with it simultaneously."( Potentiated chemotherapeutic activity of 3,6-diamino-10-methyl-acridinium by combination with glycine or DL-alpha-alanine on the Ehrlich carcinoma.
Osswald, H, 1975
)
0.25
"The present study evaluated the therapeutic effects of rebamipide alone and in combination with cimetidine on experimental gastritis established by the administration of 5 mM sodium taurocholate (TCA) for 6 months in rats."( Therapeutic effects of oral rebamipide and in combination with cimetidine on experimental gastritis in rats.
Fujimura, J; Haruma, K; Kajiyama, G; Kishimoto, S; Kobayashi, H; Machino, H; Sakurai, K; Shimamoto, T; Shimizu, S; Yamasaki, K, 1992
)
0.28
"To examine the effect of continuous fasting combined with prolonged, intermittent exercise on glucose homeostasis, 16 endurance-trained subjects, ranging in age from 18-21 years, were completely deprived of food during 81 h of field maneuvers."( The effect of prolonged intermittent exercise, combined with food deprivation, on plasma metabolite concentration.
Bashan, N; Burstein, R; Epstein, Y; Falk, B; Rubinstein, A; Shpilberg, O, 1991
)
0.28
"Sleep and waking stages in cats were studied 8 h following administration of zimeldine and alaproclate, in combination with saline or 5-hydroxy-1-tryptophan (5-HTP)."( The effects of zimeldine and alaproclate combined with a small dose of 5-HTP on waking and sleep stages in cats.
Sommerfelt, L; Ursin, R, 1987
)
0.27
"Seven patients with glycogen disease type I have been treated with nocturnal intragastric feeding combined with frequent daytime feeding."( Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.
Gröbe, H; Ullrich, K, 1983
)
0.27
"The in vitro activity of fludalanine ( MK641 ) combined with pentizidone ( MK642 ) so as to give a fludalanine /D-cycloserine ratio of 1:1 was compared with the activities of ampicillin, ticarcillin, cefuroxime, ceftazidime, and trimethoprim against 452 recent isolates and known beta-lactam- and trimethoprim-resistant strains."( In vitro activity of fludalanine combined with pentizidone compared with those of other agents.
Andrews, JM; Wise, R, 1984
)
0.27
"The phosphonopeptide alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid) exhibited synergy in vitro and in animal studies against a range of bacterial genera when combined with cephalexin."( Antibacterial properties of alafosfalin combined with cephalexin.
Atherton, FR; Hall, MJ; Hassall, CH; Holmes, SW; Lambert, RW; Lloyd, WJ; Nisbet, LJ; Ringrose, PS; Westmacott, D, 1981
)
0.26
"The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies."( Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Buter, J; Chemidlin, J; El-Khoueiry, A; Feltquate, D; Ford, S; Galbraith, S; Garrett, CR; Hayes, W; Kollia, G; LoRusso, P; Major, P; Marshall, J; Mokliatchouk, O; Nuyten, DS; Rocha-Lima, CM; Siu, LL; Syed, S; Velasquez, L, 2011
)
0.37
" We here investigated the activity of E-3810 combined with different cytotoxic agents in a MDA-MB-231 triple-negative breast cancer xenograft model."( The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M, 2013
)
0.39
" The potential use of OKN-007 in combination with neurotropic compounds such as the lanthionine ketamine esters is discussed for glioblastoma multiforme as well as for various other indications leading to dementia, such as aging, septic shock, and malaria infections."( Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.
Castro Faria Neto, HC; Floyd, RA; Hensley, K; Towner, RA; Zimmerman, GA, 2013
)
0.39
" Herein, we reported that a 67-year-old patient with intermediate stage HCC achieved the complete remission after TACE combined with brivanib therapy."( Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib.
Bai, W; Han, G; Jia, J; Qi, X; Yuan, J,
)
0.13
" The aim of the present study was to assess the relationship between this polymorphism and peripheral atherosclerosis combined with type 2 diabetes mellitus (T2DM) in an Egyptian population."( Intestinal fatty acid binding protein Ala54Thr polymorphism is associated with peripheral atherosclerosis combined with type 2 diabetes mellitus.
Abo-Elmatty, DM; Ghattas, MH; Khattab, SA; Mehanna, ET; Mesbah, NM, 2017
)
0.46
"The Thr54 allele of the FABP2 Ala54Thr polymorphism was associated with an increased incidence of peripheral atherosclerosis combined with T2DM in the population studied."( Intestinal fatty acid binding protein Ala54Thr polymorphism is associated with peripheral atherosclerosis combined with type 2 diabetes mellitus.
Abo-Elmatty, DM; Ghattas, MH; Khattab, SA; Mehanna, ET; Mesbah, NM, 2017
)
0.46
"A network meta-analysis was conducted comparing the short-term efficacies of 16 targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer (CRC)."( A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
Ba-Sang, DZ; Li, MS; Long, ZW; Qiu, J; Teng, H; Zhao, XP, 2016
)
0.43
" The results of our cluster analysis showed that chemotherapy combined with bevacizumab, cetuximab, panitumumab, conatumumab, ganitumab, or brivanib + cetuximab had better efficacies for the treatment of advanced/metastatic CRC in comparison to chemotherapy alone."( A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
Ba-Sang, DZ; Li, MS; Long, ZW; Qiu, J; Teng, H; Zhao, XP, 2016
)
0.43
"2D DIGE and MS analyses were used to reveal proteomic signatures resulting from Notch3 inhibition in HepG2 cells, combined with brivanib treatment."( Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
Baglioni, M; Bolondi, L; D'Errico, A; Giannone, FA; Giovannini, C; Gramantieri, L; Salzano, AM; Scaloni, A; Svegliati Baroni, G; Vasuri, F; Vitale, M; Zambrano, N, 2019
)
0.51
"We have demonstrated that regulation of the TCA cycle is a common mechanism in different human cancers, suggesting that Notch3 inhibitors combined with brivanib treatment may represent a strong formulation for the treatment of HCC as well as Notch3-driven cancers."( Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
Baglioni, M; Bolondi, L; D'Errico, A; Giannone, FA; Giovannini, C; Gramantieri, L; Salzano, AM; Scaloni, A; Svegliati Baroni, G; Vasuri, F; Vitale, M; Zambrano, N, 2019
)
0.51
" In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug-drug interactions (DDIs)."( Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Ceckova, M; Chen, S; Guo, L; Hofman, J; Kammerer, S; Küpper, JH; Sorf, A; Staud, F; Sucha, S; Vagiannis, D, 2019
)
0.51
" In this paper, binding free energies between two HIV (HIV-1 and HIV-2) proteases and four inhibitors are calculated by molecular mechanics/generalized Born surface area (MM/GBSA) combined with the newly developed interaction entropy (IE) approach."( Alanine scanning combined with interaction entropy studying the differences of binding mechanism on HIV-1 and HIV-2 proteases with inhibitor.
Bao, J; Cong, Y; Duan, L; Huang, K; Zhang, JZH, 2021
)
0.62
"Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician."( Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Bergan, S; Elens, L; Hesselink, DA; Langman, LJ; Lemaitre, F; Moes, DJAR; Molinaro, M; Venkataramanan, R, 2020
)
0.56
" The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19."( 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
Ahmad, SI, 2020
)
0.56
" We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19."( Remdesivir-COVID-19: drug interactions in dentistry.
Gómez-Moreno, G, 2020
)
0.56
"According to the articles reviewed, a total of 279 drugs interact with Remdesivir."( Remdesivir-COVID-19: drug interactions in dentistry.
Gómez-Moreno, G, 2020
)
0.56
" However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19."( Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021
)
0.62
" In spite of United States Food and Drug Administration's recent assent of remdesivir as the only approved agent for COVID-19, there is limited information available about the physicochemical, metabolism, transport, pharmacokinetic (PK), and drug-drug interaction (DDI) properties of this drug."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
0.62
" Subsequently, these data were used in the Drug-Drug Interaction module to simulate drug interaction potential of remdesivir with other COVID-19 drug regimens and with agents used for comorbidities."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
0.62
" We discuss the case of a hospitalized patient in the United States diagnosed with COVID-19 pneumonia who developed acute pain crisis secondary to a drug-drug interaction between tramadol and remdesivir, and we propose a possible mechanism of interaction."( Acute Pain Crisis Caused by Tramadol Remdesivir Drug-Drug Interaction.
Feely, M; Ho, I; Miller, G; Teoli, D; Thompson, V; Vlaminck, B; Wright, J, 2021
)
0.62
" Given that drug synergy often occurs through inhibition of discrete biological targets, here we propose a neural network architecture that jointly learns drug-target interaction and drug-drug synergy."( Deep learning identifies synergistic drug combinations for treating COVID-19.
Barzilay, R; Collins, JJ; Eastman, RT; Itkin, Z; Jaakkola, TS; Jin, W; Stokes, JM; Zakharov, AV, 2021
)
0.62
"In this study, the therapeutic efficacy of quercetin in combination with remdesivir and favipiravir, were evaluated in severe hospitalized COVID-19 patients."( The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
Abolnezhadian, F; Alavi, SM; Ghafourian, M; Khodadadi, A; Mahmoudian-Sani, MR; Nashibi, R; Sharhani, A; Shohan, M, 2022
)
0.72
"We retrospectively enrolled 70 unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment."( Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022
)
0.72
"Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis."( Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022
)
0.72
" This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions."( Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient.
Hirai, T; Inoue, T; Iwamoto, T; Mizuta, A; Nishikawa, K; Sasaki, T, 2022
)
0.72
" In addition, this case used amiodarone (AMD), and it has been reported that the RDV concentration increases when used in combination with AMD."( [Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir].
Bando, Y; Ishii, H; Otori, K; Yokota, N, 2022
)
0.72

Bioavailability

The aim of this work was to study the serum bioavailability of glucose and alanine after bolus injection into the peritoneal cavity in Wistar rats. The results demonstrated that the tricin-alanine-glutamic acid conjugate exhibited enhanced permeability and stability in MDCK cells.

ExcerptReferenceRelevance
" Alafosfalin was well absorbed after oral administration, but was extensively hydrolyzed to alanine and L-1-aminoethylphosphonic acid before it reached the general circulation."( Phosphonopeptides as antibacterial agents: metabolism and pharmacokinetics of alafosfalin in animals and humans.
Allen, JG; Havas, L; Leicht, E; Lenox-Smith, I; Nisbet, LJ, 1979
)
0.26
" The bioavailability of the estradiol-linked drug was determined to be 52%."( New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities?
Berger, MR; Betsch, B; Eisenbrand, G; Schmähl, D; Spiegelhalder, B, 1989
)
0.28
" The magnitude of Cel changes was related to absorption rate, which was confirmed by behaviour with hypertonic solutions, where osmotic activity in the gut was lost the sooner, the more rapid absorption rate was."( Studies on intestinal absorption by single-injection technique and continuous measurement of portal vein blood electrolyte concentration and hematocrit in the alert rat.
Aziz, O; Sommer, E, 1983
)
0.27
"In two different absorption studies, quantitative correlations between the in vitro dissolution rate and the bioavailability have been shown after single administration of various tablet compositions of alaproclate hydrochloride to healthy subjects."( Correlations between in vitro dissolution rate and bioavailability of alaproclate tablets.
Graffner, C; Lindgren, JE; Nicklasson, M, 1984
)
0.27
" Oral bioavailability was approximately 50% and was largely independent of dose."( Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans.
Allen, JG; Lees, LJ, 1980
)
0.26
" A possible mechanism is the known effect of thyroid hormones in reducing the bioavailability of insulin-like growth factor-I."( Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man.
Grøfte, T; Jørgensen, JO; Møller, N; Vilstrup, H; Wolthers, T, 1996
)
0.29
"The aim of this work was to study the serum bioavailability of glucose and alanine after bolus injection into the peritoneal cavity in Wistar rats and to determine the influence of their metabolism on the rate of absorption of these nutrients."( A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications.
Mahedero, G; Mariñõ, E; Morán, JM; Ribeiro, JM; Salas, J; Vinagre, LM,
)
0.13
" The constants of absorption from peritoneal cavity (Ka) and elimination from plasma (Ke) and the serum absolute bioavailability (BA(a)) after 8 h were calculated assuming a bicompartment pharmacokinetic model."( A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications.
Mahedero, G; Mariñõ, E; Morán, JM; Ribeiro, JM; Salas, J; Vinagre, LM,
)
0.13
"The absorption rate from peritoneal cavity is nearly 10-fold higher than the elimination rate from plasma for the three substrates."( A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications.
Mahedero, G; Mariñõ, E; Morán, JM; Ribeiro, JM; Salas, J; Vinagre, LM,
)
0.13
"The bioavailability of insulin-like growth factor I (IGF-I) in the serum and tissues is controlled by members of the IGF binding protein family (IGFBP)."( Total alanine-scanning mutagenesis of insulin-like growth factor I (IGF-I) identifies differential binding epitopes for IGFBP-1 and IGFBP-3.
Dubaquié, Y; Lowman, HB, 1999
)
0.3
" The rate of absorption decreased in proportion to the fall of amino acid concentration."( Absorption of leucine, alanine and lysine from the rumen.
Fébel, H; Rimanóczy, A; Veresegyházy, T, 2001
)
0.31
" GS-7340 (9-[(R)-2-[[[[(S)-1-(isopropoxycarbonyl)ethyl] amino] phenoxy-phosphinyl]-methoxy] propyl] adenine) is a prodrug which is orally bioavailable in dogs as the intact prodrug and has demonstrated anti-HIV activity in cell culture of over 1000-fold greater than that of PMPA."( Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood.
Eisenberg, EJ; He, GX; Lee, WA,
)
0.13
"The practical synthesis of a mixed phenoxy-amidate derivative of PMPA with high oral bioavailability and favorable pharmacokinetics is described."( Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340.
Chapman, H; Kernan, M; Prisbe, E; Rohloff, J; Sparacino, M; Terhorst, T; Yu, R,
)
0.13
" Results from two phase I trials of the compound (single ascending dose and steady state at three doses), completed in March 2000, demonstrated that the drug is well tolerated with good bioavailability and linear pharmacokinetics [359652]."( Safinamide (Newron Pharmaceuticals).
Chazot, PL, 2001
)
0.31
"A series of water-soluble L-lysyl- and L-alanyl-amide prodrugs of the lipophilic antitumor 2-(4-aminophenyl)benzothiazoles has been synthesized to address formulation and bioavailability issues related to the desired parenteral administration of the chosen clinical candidate."( Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
Hutchinson, I; Jennings, SA; Stevens, MF; Vishnuvajjala, BR; Westwell, AD, 2002
)
0.31
" We have hypothesized that mitochondrial lysine degradation is regulated by bioavailability of 2-oxoglutarate in the same compartment, and our studies in physiologic fluid derived from patients with the above described disorders supports our hypothsis."( Plasma lysine concentration and availability of 2-ketoglutarate in liver mitochondria.
Kamoun, P; Rabier, D; Richard, V; Saudubray, JM, 2002
)
0.31
" Oral bioavailability was variable and may be a result of binding to circulating plasma proteins."( Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
Colletti, A; DeLaszlo, SE; Egger, LA; Hagmann, WK; Kidambi, U; Kopka, IE; Lanza, T; Levorse, D; Lin, LS; Lyons, K; MacCoss, M; Magriotis, PA; McCauley, E; Mills, SG; Mumford, RA; Owens, K; Schmidt, JA; Stearns, R; Teffera, Y; Tong, S; Van Riper, G; Vincent, S; Young, D, 2002
)
0.31
" In conclusion, the combinatorial use of C12 with Tau or L-Gln could lead to a novel formulation improving the bioavailability of poorly absorbable drugs without any serious local damages."( Combinatorial use of sodium laurate with taurine or L-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages.
Higaki, K; Kimura, T; Minami, T; Miyake, M; Odomi, M; Ogawara, K; Oka, Y; Toguchi, H, 2003
)
0.32
" In particular, these calpain inhibitors showed oral bioavailability in rats as demonstrated by N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethylaminomethylphenyl)ethen-1-yl]benzamide (5d)."( Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability.
Beckenbach, E; Bopp, S; Hofmann, HP; Kartal, A; Kästel, C; Lindner, T; Lubisch, W; Metz-Garrecht, M; Möller, A; Reeb, J; Regner, F; Vierling, M, 2003
)
0.32
" Superoxide is known to alter the bioavailability of NO, and its contribution to the GPIIb/IIIa dependent increase in NO release was determined."( Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti, S; Clutton, P; Cox, D; Freedman, JE; Mascelli, MA; Varghese, S, 2004
)
0.32
"To develop the safe formulation that can safely improve bioavailability of poorly absorbable drugs and that is practically available, we prepared the suppositories of rebamipide, a poorly soluble and poorly absorbable antiulcer drug, by employing the combinatorial use of sodium laurate (C12), an absorption enhancer, with taurine (Tau) or L-glutamine (L-Gln), an adjuvant exerting the cytoprotective action."( Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine.
Higaki, K; Kamada, N; Kimura, T; Minami, T; Miyake, M; Mukai, T; Odomi, M; Ogawara, K; Oka, Y; Toguchi, H, 2004
)
0.32
" This study was conducted to examine if the rebamipide lysinate salt form would exhibit improved solubility profiles and higher oral bioavailability compared with rebamipide free acid."( Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats.
Han, HS; Jun, YS; Kim, CH; Lee, KC; Rho, JI; Shin, BS; Yoo, SD; Yoon, CH, 2004
)
0.32
" After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an intravenous dose of tenofovir was 17%."( Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
Cihlar, T; Cundy, KC; Eisenberg, E; He, GX; Lee, WA; Mulato, A; Swaminathan, S, 2005
)
0.33
" Its relatively low bioavailability in different animal species drove the need for an effective prodrug form that would produce a therapeutic response at lower doses for the treatment of anxiety disorders."( Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
Bueno, AB; Catlow, J; Clay, MP; Coffey, DS; Collado, I; Dantzig, AH; de Dios, A; Domínguez, C; Herin, MF; Jiang, H; Lindstrom, T; Martín, JA; Martín, LM; Martínez-Grau, MA; Monn, JA; Montero, C; Pedregal, C; Schoepp, DD; Stratford, RE; Tabas, LB; Tizzano, JP; Wright, RA, 2005
)
0.33
" Triiodothyronine (T(3)), formed chiefly by deiodination of T(4), is the active hormone at the nuclear receptor, and it is generally accepted that deiodination is the major pathway regulating T(3) bioavailability in mammalian tissues."( Alternate pathways of thyroid hormone metabolism.
Chopra, IJ; Green, WL; Hays, MT; Huang, WS; Wu, SY, 2005
)
0.33
" Although animal and human studies demonstrate potential therapeutic utility, poor oral bioavailability is a limiting factor in the clinical development of these compounds."( Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Hart, JC; Johnson, BG; Knitowski, KM; McKinzie, DL; Perkins, EJ; Rorick-Kehn, LM; Schoepp, DD, 2006
)
0.33
" Although Tau tended to attenuate the absorption-enhancing effect of C12, several C12-Tau suppositories kept high bioavailability values, which were much higher than control."( Optimization of suppository preparation containing sodium laurate and taurine that can safely improve rectal absorption of rebamipide.
Higaki, K; Kamada, N; Kato, Y; Kimura, T; Minami, T; Miyake, M; Mukai, T; Odomi, M; Ogawara, K; Oka, Y; Toguchi, H; Yamazaki, H, 2006
)
0.33
" Relative oral bioavailability (RBV) values, with the L-isomer of Met and Cys set at 100% (isosulfurous basis), are near 100% for D-Met for animals but only about 30% for humans."( Comparative species utilization and toxicity of sulfur amino acids.
Baker, DH, 2006
)
0.33
" As N-methylation introduces different flexibility and lipophilicity, it can also improve the bioavailability (the ADMET profile)."( N-methylated cyclic pentaalanine peptides as template structures.
Chatterjee, J; Kessler, H; Mierke, D, 2006
)
0.33
"This paper describes three methods to bioassay safinamide (CAS 133865-89-1) in biological fluids of humans and laboratory animals for pharmacokinetic, toxicokinetic and bioavailability studies."( Bioassay of safinamide in biological fluids of humans and various animal species.
Dal Bo, L; Fibbioli, M; Marzo, A; Mazzucchelli, P, 2006
)
0.33
"]hexen-2,6-dicarboxylic acid, also known as LY544344, was discovered to improve the oral bioavailability of the parent drug (+)-2-aminobicyclo[3."( Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass
Abraham, T; Perkins, EJ, 2007
)
0.34
" VP-0502AL is predicted to become a new highly bioavailable anti-AIDS drug candidate and/or lead compound."( Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats.
Chae, KA; Cho, HJ; Kim, JS; Lee, H; Seo, DC; Shin, HC; Sung, JM, 2007
)
0.34
" The oral disintegrating tablet formulation of selegiline allows pregastric absorption, minimizing first-pass metabolism, thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites."( Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Chen, JJ; Fernandez, HH, 2007
)
0.34
"A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound."( Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa
Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; D'Arienzo, C; Derbin, G; Fan, J; Fargnoli, J; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Marathe, P; Mortillo, S; Qian, L; Robl, JA; Shi, Z; Wautlet, BS; Wei, D; Wu, L; Zhang, Y; Zheng, X, 2008
)
0.35
"Selective endothelial insulin resistance is sufficient to induce a reduction in NO bioavailability and endothelial dysfunction that is secondary to increased generation of reactive oxygen species."( Effect of endothelium-specific insulin resistance on endothelial function in vivo.
Anilkumar, N; Crossey, PA; Douglas, G; Duncan, ER; Ezzat, VA; Kearney, MI; Kearney, MT; Poston, L; Shah, AM; Walker, S; Wheatcroft, SB, 2008
)
0.35
"The limited oral bioavailability of the potent and selective group II metabotropic glutamate (mGlu) 2/3 receptor agonist, (1S,2S,5R,6S)-2-aminobicyclo[3."( Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxy
Eriksson, AH; Pak, YA; Perkins, EJ; Sawada, G; Varma, MV; Zimmerman, CL, 2009
)
0.35
" The oral bioavailability of brivanib varied among species (22-88%) and showed dissolution rate-limited absorption even when combined with organic co-solvents."( Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Bhide, R; D'Arienzo, C; Fargnoli, J; Kamath, AV; Marathe, PH; Zhang, Y, 2009
)
0.35
" Its alanyl prodrug, LY544344, showed high affinity to the intestinal peptide transporter PEPT1, and improved the oral bioavailability of LY354740 in various animal models."( The intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: in situ rat intestinal perfusion studies.
Eriksson, AH; Perkins, EJ; Varma, MV; Zimmerman, CL, 2010
)
0.36
" Pine and oak wood increase the immobilization of the pesticides studied, but they also limit their bioavailability in soil by decreasing their degradation rate in amended soil."( Influence of pine or oak wood on the degradation of alachlor and metalaxyl in soil.
Azejjel, H; Marín-Benito, JM; Ordax, JM; Rodríguez-Cruz, MS; Sánchez-Martín, MJ, 2012
)
0.38
" Various phosphonate prodrugs were explored without success, until a novel phosphonic diamide prodrug approach was implemented, which delivered compound 30j with good oral bioavailability (OBAV) (22-47%)."( Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Cashion, DK; Dang, Q; DaRe, J; Erion, MD; Fan, Y; Gibson, T; Jacintho, JD; Jiang, T; Kasibhatla, SR; Lemus, R; Li, H; Li, W; Liu, Y; Potter, SC; Sun, Z; Taplin, F; Tian, F; van Poelje, PD, 2011
)
0.37
"Determining the effect of selenium (Se) chemical form on uptake, transport, and glutathione peroxidase activity in human intestinal cells is critical to assess Se bioavailability at nutritional doses."( Chemical form of selenium affects its uptake, transport, and glutathione peroxidase activity in the human intestinal Caco-2 cell model.
Cheng, WH; Combs, GF; Jackson, MI; Zeng, H, 2011
)
0.37
"Knowledge about the enantioselective bioavailability of chiral pesticides in soil invertebrates facilitates more accurate interpretation of their environmental behaviors."( Enantioselective bioaccumulation and toxic effects of metalaxyl in earthworm Eisenia foetida.
Diao, J; Liu, D; Xu, P; Zhou, Z, 2011
)
0.37
" The results demonstrated that the tricin-alanine-glutamic acid conjugate exhibited enhanced permeability, stability in MDCK cells, and excellent bioavailability after oral administration in Crl:CD (SD) male rats."( Increased bioavailability of tricin-amino acid derivatives via a prodrug approach.
Koketsu, M; Muto, Y; Ninomiya, M; Tanaka, K; Tsuchida, Y; Watanabe, K, 2011
)
0.37
" Consequently, the bioavailability of rebamipide is under 10% in humans."( Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.
Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Tung, NT, 2011
)
0.37
" The bioavailability and efficacy of RBM solid dispersion were evaluated in a rat model."( Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.
Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Tung, NT, 2011
)
0.37
" Bioavailability and efficacy of rebamipide were increased significantly by solubility enhancement of the drug."( Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.
Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Tung, NT, 2011
)
0.37
" A simulation model and an isothermal titration calorimetry method were developed to assess the bioavailability risk and strength of drug-excipient binding interaction, independent of physiological salt concentration consideration."( Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Badawy, S; Bindra, DS; Comezoglu, SN; Doyle, ML; Narang, AS; Varia, S; Yamniuk, AP; Zhang, L, 2012
)
0.38
" Absorption simulation predictions of no effect of CCS binding on BA's bioavailability were confirmed by a monkey pharmacokinetic study."( Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Badawy, S; Bindra, DS; Comezoglu, SN; Doyle, ML; Narang, AS; Varia, S; Yamniuk, AP; Zhang, L, 2012
)
0.38
"A pH-dependent and reversible weak drug-excipient binding interaction is unlikely to affect the oral bioavailability of high dose drugs."( Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Badawy, S; Bindra, DS; Comezoglu, SN; Doyle, ML; Narang, AS; Varia, S; Yamniuk, AP; Zhang, L, 2012
)
0.38
" PK and PD studies in Sprague-Dawley rats revealed that the bioavailability of the drug using optimal SD was about twofold higher than that of reference product, and the irritation area of stomach was significantly reduced in the ulcer-induced rat model using optimal SD as compared to the reference product."( Physicochemical, pharmacokinetic and pharmacodynamic evaluations of novel ternary solid dispersion of rebamipide with poloxamer 407.
Chi, SC; Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Tung, NT, 2013
)
0.39
" Since HAI regulates L-Arg bioavailability for NO biosynthesis, it is a potential drug target for the treatment of cardiovascular diseases such as atherosclerosis."( Binding of the unreactive substrate analog L-2-amino-3-guanidinopropionic acid (dinor-L-arginine) to human arginase I.
Christianson, DW; D'Antonio, EL, 2012
)
0.38
"Knowledge about the enantioselective bioavailability of chiral pesticides in aquatic organisms facilitates more accurate interpretation of their environmental behaviors."( Enantioselective bioaccumulation and degradation of sediment-associated metalaxyl enantiomers in Tubifex tubifex.
Di, S; Diao, J; Liu, T; Zhou, Z, 2013
)
0.39
"The purpose of this study was to improve the gastric solubility and bioavailability of rebamipide (RBM) by preparing the RBM solid dispersion tablet (RBM-SDT) from solid dispersion powder prepared by spray-drying technique."( Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability.
Choi, HG; Choi, IS; Choi, JY; Kim, JO; Pradhan, R; Tran, TH; Yong, CS, 2015
)
0.42
" Our findings show that addition of BC affected the final enantioselective behavior of metalaxyl in soil indirectly by reducing its bioavailability through sorption, and to a greater extent than OMWc."( Environmental fate of the fungicide metalaxyl in soil amended with composted olive-mill waste and its biochar: An enantioselective study.
Celis, R; Cox, L; Gámiz, B; Hermosín, MC; Pignatello, JJ, 2016
)
0.43
" The enhanced sorption in HT-ELA-amended soils reduced the bioavailability of metalaxyl enantiomers and their leaching in the soils, mitigating the particularly high leaching potential of the more persistent S enantiomer."( Evaluation of an organo-layered double hydroxide and two organic residues as amendments to immobilize metalaxyl enantiomers in soils: A comparative study.
Celis, R; Cornejo, J; López-Cabeza, R, 2016
)
0.43
" Adding these materials to soil requires understanding the process of pesticide sorption-desorption by wood-soils, as sorption capacity could increase, with changes in pesticide bioavailability and final fate."( Study of processes influencing bioavailability of pesticides in wood-soil systems: Effect of different factors.
Arienzo, M; Herrero-Hernández, E; Marín-Benito, JM; Rodríguez-Cruz, MS; Sánchez-Martín, MJ, 2017
)
0.46
" The ADME properties of these active molecules were also predicted to enhance the knowhow of the oral bioavailability, indicating good bioavailability of the active entities."( Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
Bhatt, JD; Chudasama, CJ; Dixit, BC; Dixit, RB; Patel, BD; Patel, TS; Patel, UH; Vanparia, SF, 2017
)
0.46
"Rebamipide (RBP) is a potent anti-ulcer and anti-oxidative agent, which is a BCS class IV drug with a low oral bioavailability of less than 10%."( Capmul MCM/Solutol HS15-Based Microemulsion for Enhanced Oral Bioavailability of Rebamipide.
Cho, HJ; Kim, DD; Kim, KT; Lee, JY; Park, JH; Yoon, IS, 2017
)
0.46
" Lactobacillus crispatus actively transported tenofovir leading to a loss in drug bioavailability and culture supernatants from Gardnerella vaginalis, but not Atopobium vaginae, blocked tenofovir endocytosis."( Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
Cameron, SA; Cheshenko, N; Frank, B; Fredricks, D; Herold, BC; Keller, MJ; Mesquita, PM; Reagle, K; Sinclair, S; Srinivasan, S; Taneva, E; Weinrick, B, 2018
)
0.48
"Rebamipide has low oral bioavailability (10%) due to its low solubility and permeability."( Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects.
Guda, S; Narala, A; Veerabrahma, K, 2019
)
0.51
" BIC has demonstrated a high genetic barrier to resistance development in vitro, can be administered with or without food, and has a bioavailability of > 70%."( Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J, 2019
)
0.51
" Although substantial evidence has been collected about the potential usefulness of BCAAs in supporting muscle function and structure, dietary supplements containing BCAAs alone may not be effective in controlling muscle protein turnover, due to the rate-limiting bioavailability of other AAs involved in BCAAs metabolism."( Ergogenic Effect of BCAAs and L-Alanine Supplementation: Proof-of-Concept Study in a Murine Model of Physiological Exercise.
Allegretti, M; Aramini, A; Bianchini, G; Boccanegra, B; Brandolini, L; Camerino, GM; Cappellari, O; Conte, E; De Bellis, M; De Luca, A; Mantuano, P; Mele, A; Sanarica, F, 2020
)
0.56
" Rebamipide, classified into BCS class IV, is one of those drugs which provide very low bioavailability and/or the difficulty of formulation for oral administration."( Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation.
Higaki, K; Maruyama, M; Masuda, K; Ogawara, KI; Okawa, S; Sumimoto, Y, 2021
)
0.62
"In this study, a novel rebamipide-loaded spray-dried microsphere (RSM) with enhanced drug solubility and oral bioavailability has been developed utilizing meglumine, an alkalizing agent."( Development of rebamipide-loaded spray-dried microsphere using distilled water and meglumine: physicochemical characterization and pharmacokinetics in rats.
Cho, JH; Choi, HG; Ko, DW, 2021
)
0.62
" The reduced uptake was mainly attributed to the decreased bioavailability of R-MET and S-MET."( Biochar decreased enantioselective uptake of chiral pesticide metalaxyl by lettuce and shifted bacterial community in agricultural soil.
Fang, S; Li, F; Li, Y; Suo, F; Wang, X; Yin, S; You, X; Zhang, C; Zheng, H, 2021
)
0.62
" Potent orally bioavailable antiviral drugs for early treatment of SARS-CoV-2 infection are urgently needed, and several, including molnupiravir and PF-07321332, are currently in clinical development."( Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
Beadle, JR; Carlin, AF; Clark, AE; Garretson, AF; Hostetler, KY; Leibel, SL; McMillan, RE; McVicar, RN; Murphy, J; Schooley, RT; Smith, VI; Valiaeva, N; Xie, J; Zhang, XQ, 2021
)
0.62
"Rebamipide (REB) a potent anti-ulcer agent, has not been exploited to its full potential, owing to it extremely poor solubility, leading to highly diminutive bioavailability (<10%)."( Engineering a Remedy to Modulate and Optimize Biopharmaceutical Properties of Rebamipide by Synthesizing New Cocrystal: In Silico and Experimental Studies.
Chadha, R; Dureja, J; Jindal, A; Karan, M; Singh, R; Tomar, S, 2021
)
0.62
"5 folds enhancement in relative bioavailability and remarkable amplification in anti-ulcer, anti-inflammatory and the antioxidant potential of these cocrystals were observed."( Engineering a Remedy to Modulate and Optimize Biopharmaceutical Properties of Rebamipide by Synthesizing New Cocrystal: In Silico and Experimental Studies.
Chadha, R; Dureja, J; Jindal, A; Karan, M; Singh, R; Tomar, S, 2021
)
0.62
" Here, we demonstrate the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parent nucleoside of remdesivir, which targets the highly conserved virus RNA-dependent RNA polymerase."( Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
Babusis, D; Bannister, R; Baric, RS; Barrett, KT; Bilello, JP; Bleier, BJ; Brown, AJ; Chun, K; Cihlar, T; Conrad, WS; Dong, S; Du Pont, V; Feng, JY; Gully, KL; Kalla, R; Mackman, RL; Martinez, DR; May, SR; Meganck, RM; Montgomery, SA; Moreira, FR; Murakami, E; Schäfer, A; Sheahan, TP; Subramanian, R; Tang, J; Won, JJ; Zweigart, MR, 2022
)
0.72
" Unexpectedly, despite enhanced dissolution rate in a controlled manner, a designed bilayer tablet had no dose- and dosage form dependent in vivo bioavailability in beagle dogs as compared with IR 100 mg RBM reference tablet."( Design and evaluation of in vivo bioavailability in beagle dogs of bilayer tablet consisting of immediate release nanosuspension and sustained release layers of rebamipide.
Cao, QR; Cui, JH; Jin, G; Jung, M; Lee, BJ; Ngo, HV; Park, C; Wang, J, 2022
)
0.72
" Tenofovir has a very low oral bioavailability following oral administration."( Treatment of chronic hepatitis B: virological and pharmacological aspects
Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G, 2022
)
0.72
"A crossover, randomized trial in healthy adults (NCT04244448) investigated the bioavailability of two off-label uses of BIC/TAF/FTC (50/200/25 mg), dissolved in water or crushed in apple compote, compared with the solid tablet."( Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C, 2022
)
0.72

Dosage Studied

Electron Paramagnetic Resonance (EPR) study of irradiated l-alanine showed differences in dose-response curves. The intestinal cotransport kinetics for glutamine is different from that of glucose and alanine.

ExcerptRelevanceReference
" Salbutamol was given as an infusion in the same dosage as is used to inhibit uterine contractions in cases of premature labor and in obstetric emergencies."( The immediate effect of a beta-adrenergic agonist (salbutamol) on carbohydrate and lipid metabolism during the third trimester of pregnancy.
Joelsson, I; Larsson, A; Lunell, NO; Persson, B, 1977
)
0.26
" The inhibition reaction, readable as an 'all-or-none' phenomenon, follows a dose-response relationship for cultures affected by beta-2-thienylalanine, and is unaffected by the growth phase of the culture."( Differentiation of pathogenic, gram-negative, bacterial genera in the presence of beta-2-thienylalanine.
Brown, KJ; Lines, DR, 1976
)
0.26
" A substituent NH2-terminal tripeptide and amides of the NH2-terminal amino acids, which are devoid of chemotactic and deactivating activities, reversibly inhibit the tetrapeptide stimulus in a dose-response fashion."( Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis.
Austen, KF; Goetzl, EJ, 1976
)
0.26
" The monotherapy with the applied amino acids in the same dosage showed no tumor inhibition."( Potentiated chemotherapeutic activity of 3,6-diamino-10-methyl-acridinium by combination with glycine or DL-alpha-alanine on the Ehrlich carcinoma.
Osswald, H, 1975
)
0.25
" 266, 10880-10887) identified an estrogen receptor (ER) mutant which had a similar binding affinity for estradiol as wild-type ER but displayed a dose-response shift for estradiol in transactivation studies."( Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation.
Katzenellenbogen, BS; Reese, JC, 1992
)
0.28
" Female Sprague-Dawley rats were orally dosed with mirex (12."( Mirex exposure inhibits the uptake of estradiol-17 beta(beta-D-glucuronide), taurocholate, and L-alanine into isolated rat hepatocytes.
Teo, S; Vore, M, 1990
)
0.28
" To assess the possible dose-response of such short-term bolus administration of GH, six healthy, male subjects were each studied thrice for 4 1/2 hours after an intravenous (IV) bolus of either 70, 140, or 350 micrograms GH, resulting in peak GH concentrations of 10, 15, and 34 micrograms/L."( Dose-response studies on the metabolic effects of a growth hormone pulse in humans.
Jørgensen, JO; Møller, J; Møller, N; Pørksen, N; Schmitz, O, 1992
)
0.28
" The dose-response curves of these substrates suggest that the intestinal cotransport kinetics for glutamine is different from that of glucose and alanine."( Transport of glutamine, alanine and glucose by rabbit intestinal membrane.
Freire Júnior, JE; Lima, AA; Soares, AM, 1991
)
0.28
" Examination by EPR silicone-alanine pellets irradiated with 60Co gamma rays in the dose range 10 to 10(6) Gy shows that the proposed silicone binder does not affect typical alanine dose-response curves."( Use of alanine-silicone pellets for electron paramagnetic resonance gamma dosimetry.
Flores, J; Galindo, S, 1991
)
0.28
" Compared with the C test, maintenance of glucagon level had only small and inconsistent effects on glucose Rd, but induced a shift to the right of the dose-response curve to insulin of EGP (apparent ED50: C test, 10."( Interactions of glucagon and free fatty acids with insulin in control of glucose metabolism.
Beylot, M; Chambrier, C; Cohen, R; Picard, S; Riou, JP; Vidal, H, 1990
)
0.28
"Time- and dose-response studies were conducted to determine the effects of the antidepressant and antipanic drug phenelzine (a monoamine oxidase inhibitor) on whole brain levels of the aliphatic amino acid alanine."( Long-lasting elevation of alanine in brain produced by the antidepressant phenelzine.
Baker, GB; Coutts, RT; Dewhurst, WG; Wong, JT, 1990
)
0.28
" Therefore, the conversion of 14C-alanine into 14C-glucose was also determined in hypophysectomized rats dosed with TCDD (125 micrograms/kg) and given corticosterone (25 micrograms/ml in drinking water)."( Reduced gluconeogenesis in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats.
Gorski, JR; Rozman, K; Weber, LW, 1990
)
0.28
" We conclude that the duration and dosage of glutamine administration (equivalent to 26 gm glutamine per day in a patient weighing 70 kg) used in this study are not sufficient to restore glutamine deficiency of the skeletal muscle in the depleted state."( Glutamine-containing dipeptides as infusion substrates in the septic state.
Fürst, P; Karner, J; Ollenschläger, G; Roth, E; Simmel, A, 1989
)
0.28
" Given intraperitoneally at the single dosing range of 10-100 mg/kg, OPC-12759 inhibited the formation of these acute gastric ulcer models."( Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats.
Imaizumi, T; Ishiyama, H; Kanbe, T; Yabuuchi, Y; Yamasaki, K, 1989
)
0.28
" The dosage of both zimeldine and alaproclate was 200 mg daily."( Alaproclate a novel antidepressant? A biochemical and clinical comparison with zimeldine.
Aberg-Wistedt, A; Alvariza, M; Bertilsson, L; Malmgren, R; Wachtmeister, H, 1985
)
0.27
" The peak FL concentration is proportional to the dose of DFA; repeated daily dosing of DFA appears to cause neither saturation nor induction of metabolic pathways."( Oxidative and defluorinative metabolism of fludalanine, 2-2H-3-fluoro-D-alanine.
Darland, GK; Hajdu, R; Kahan, FM; Kropp, H; Vandenheuvel, WJ; Walker, RW,
)
0.13
" In conclusion, GNG and glycogenolysis were similarly sensitive to stimulation by glucagon in vivo, and the dose-response curves were markedly parallel."( Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo.
Brown, L; Cherrington, AD; Davis, MA; Donahue, P; Hendrick, GK; Lacy, DB; Lacy, WW; Steiner, KE; Stevenson, RW; Williams, PE, 1987
)
0.27
" Both analogs shifted the hANP-(1-28) dose-response curve to the left."( Atrial natriuretic peptides: the role of phenylalanine on biological activity.
Craven, TG; Kem, DC; Schiebinger, RJ, 1988
)
0.27
" By contrast, comparable oral dosing with BMAA precipitates tremor and weakness, bradykinesia and behavioural changes, with conduction deficits in the principal motor pathway."( Discovery and partial characterization of primate motor-system toxins.
Hugon, J; Ludolph, A; Nunn, PB; Ross, SM; Roy, DN; Schaumburg, HH; Spencer, PS, 1987
)
0.27
" These studies indicate that insulin sensitivity of AA is similar to that of glucose disposal and that AA responses to insulin exhibit a physiologically relevant, dose-response relationship."( Insulin dose-dependent reductions in plasma amino acids in man.
Fukagawa, NK; Minaker, KL; Rowe, JW; Young, VR, 1986
)
0.27
" Plasma free insulin profiles reflected the dosage patterns and there was no change in insulin metabolic clearance rate in pregnancy."( Observations on the metabolic basis for altered insulin dose distribution in diabetic pregnancy.
Frier, BM; Home, PD; Johnstone, FD; Steel, JM; Young, RJ,
)
0.13
"Eight 15N-labeled nonessential amino acids plus 15NH4Cl were administered over a 10-h period to four healthy adult males using a primed-constant dosage regimen."( Metabolism of nonessential 15N-labeled amino acids and the measurement of human whole-body protein synthesis rates.
Albina, JA; Dempsey, DT; Melnick, G; Settle, RG; Stein, TP, 1986
)
0.27
" In addition a dose-response effect of alanine was observed."( Alanine decreases the protein requirements of infants with inborn errors of amino acid metabolism.
Algert, S; Kelts, DG; Nyhan, WL; Prodanos, C; Wolff, JA, 1985
)
0.27
" The log dose-response curve for depolarization was sigmoid with a mean ED(50) of 12."( Depolarizing actions of gamma-aminobutyric acid and related compounds on rat superior cervical ganglia in vitro.
Bowery, NG; Brown, DA, 1974
)
0.25
" With the exception of gamma-amino butyric acid and L-alanine benzyl ester all analogues which had appreciable activity gave dose-response curves parallel to L-alanine."( Isolation and identification of pharmacologically active amino acids in skin and their structure-activity relationship on the guinea-pig ileum.
Lewis, GP; McMartin, C; Rosenthal, SR; Yates, C, 1972
)
0.25
"" The precision of the method derives from a direct comparison between the cumulative dose-response curve of an agonist of unknown potency acting on one hemibladder and that of a reference compound acting on the contralateral hemibladder."( A sensitive hydroosmotic toad bladder assay. Affinity and intrinsic activity of neurohypophyseal peptides.
Eggena, P; Schwartz, IL; Walter, R, 1968
)
0.25
" The dose-response curve for cAMP formation stimulated by epinephrine was shifted 1 log unit to the right in uremic muscle and adenylyl cyclase stimulation by epinephrine was shifted 1 log unit."( Skeletal muscle amino acid metabolism in chronic uremia.
Garber, AJ; Maillet, C, 1980
)
0.26
" Therapeutic response to both drugs has been linked to plasma concentration of parent compound, and a nonlinear dose-response relationships might exist at high doses."( Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Powis, G, 1983
)
0.27
" Calcium transport rates could be partially restored by in vivo administration of 1,25-dihydroxyvitamin D-3 at a dosage which did not affect vesicular calcium uptake in control animals."( Calcium and glucose uptake in rat small intestinal brush-border membrane vesicles. Modulation by exogenous hypercortisolism and 1,25-dihydroxyvitamin D-3.
Birkenhäger, JC; Braun, HJ; De Jonge, HR, 1984
)
0.27
" Dose-response curves for L-amino acids showed simple saturation."( Sodium-dependent sugar and amino acid transport in isolated goldfish intestinal epithelium: electrophysiological evidence against direct interactions at the carrier level.
Albus, H; Lippens, F; Siegenbeek van Heukelom, JS, 1983
)
0.27
" With beta-2-t added to liquid cultures, however, dose-response growth relationships were exhibited by all three genera."( Comparison of liquid and agar-solidified defined media regarding the physiological mechanism by which beta-2-thienylalanine inhibits growth of Escherichia, Shigella, and Salmonella cultures.
Brown, KJ; Elliott, RB; Lines, DR; Tannock, GW, 1980
)
0.26
" After block of desensitization by concanavalin-A, dose-response analysis for activation of kainate-preferring receptors in DRG neurons gave the potency sequence trifluoromethyl > iodo > bromo approximately chloro > nitro approximately cyano > kainate > methyl > fluoro > (R,S)-AMPA >> willardiine; EC50 values for the most and least potent willardiine derivatives, 5-trifluoromethyl (70 nM) and 5-fluoro (69 microM), differed 1000-fold."( Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons.
Jane, DE; Mayer, ML; Watkins, JC; Wong, LA, 1994
)
0.29
" GABA dose-response characteristics of wild type and mutant receptors were very similar."( A unique amino acid of the Drosophila GABA receptor with influence on drug sensitivity by two mechanisms.
ffrench-Constant, RH; Jackson, MB; Zhang, HG, 1994
)
0.29
" Co-expression of the mutants with beta 2 and gamma 2 subunits in human embryonic kidney cells produced functional receptors which are similar to the wild type in their sensitivity to a benzodiazepine agonist (U-92330), insensitivity to Zn, anion permeability, and GABA dose-response profiles as monitored with the whole cell patch clamp technique."( Acceleration of GABA-dependent desensitization by mutating threonine 266 to alanine of the alpha 6 subunit of rat GABAA receptors.
Altman, RA; Binder, JA; Dillon, GH; Im, HK; Im, WB; Pregenzer, JF, 1995
)
0.29
"Time- and dose-response analyses were undertaken to investigate the effects of the substituted hydrazine monoamine oxidase (MAO) inhibitors iproniazid and nialamide on the following: MAO-A and -B activity; levels of gamma-aminobutyric acid (GABA), alanine (ALA), and the neurotransmitter amines dopamine, noradrenaline, and 5-hydroxytryptamine (serotonin) and their acid metabolites; and the activity of GABA-transaminase and ALA-transaminase."( Effects of two substituted hydrazine monoamine oxidase (MAO) inhibitors on neurotransmitter amines, gamma-aminobutyric acid, and alanine in rat brain.
Baker, GB; Paetsch, PR; Takahashi, S; Todd, KG; Yamada, N, 1993
)
0.29
" PTH increased Pi transport with a biphasic dose-response curve."( Pi transport regulation by chicken growth plate chondrocytes.
Bonjour, JP; Caverzasio, J; Montessuit, C, 1994
)
0.29
" The first (L) represented a typical multiphasic dose-response with low- and high-concentration inhibition separated by a sharp zonal loss of inhibition that could be abolished by alanine."( Multiphasic control of proteolysis by leucine and alanine in the isolated rat hepatocyte.
Kadowaki, M; Miotto, G; Mortimore, GE; Siliprandi, N; Venerando, R, 1994
)
0.29
" The dose-response relationship for the IP3 response of L-Cys and L-Ala in the range from 10 nM to 1 mM is consistent with previous electrophysiological and ligand binding experiments."( Rapid kinetic measurements of second messenger formation in olfactory cilia from channel catfish.
Boekhoff, I; Breer, H; Restrepo, D, 1993
)
0.29
" The dose-response relationship of indomethacin for inhibition of prostaglandin formation and rebamipide-induced protection correlated well and 5 mg/kg indomethacin completely prevented the protective effect of rebamipide."( Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats.
Kleine, A; Kluge, S; Peskar, BM, 1993
)
0.29
", 500, 250, and 50 micrograms/ml, in the presence of bioactivation, and at the highest dosage (500 micrograms/ml) in the absence of bioactivation."( In vitro transforming effect of the fungicides metalaxyl and zineb.
Bonora, B; Colacci, A; Grilli, S; Perocco, P, 1995
)
0.29
" Both antagonists produced parallel shifts in agonist dose-response curves."( Pharmacological antagonism of the actions of group II and III mGluR agonists in the lateral perforant path of rat hippocampal slices.
Bushell, TJ; Collingridge, GL; Garthwaite, J; Jane, DE; Tse, HW; Watkins, JC, 1996
)
0.29
" The T88A and T88S mutant receptor fully stimulated adenylyl cyclase, with the dose-response curves to CGS 21680 highly shifted to the right."( Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
Jacobson, KA; Jiang, Q; Kim, J; Van Rhee, AM; Wess, J; Yehle, S, 1996
)
0.29
" Using the rat cortical wedge preparation, the latter series of experiments showed the expected rightward parallel shifts of the dose-response curves."( Functional partial agonism at ionotropic excitatory amino acid receptors.
Ebert, B; Krogsgaard-Larsen, P; Madsen, U; Søby, KK, 1996
)
0.29
" Rats were given hydrocortisone 21-acetate or the dosing vehicle and were infused with alanine (AA) or alanyl-glutamine (AG) at the same concentrations and rates (1."( Alanyl-glutamine prevents muscle atrophy and glutamine synthetase induction by glucocorticoids.
Hickson, RC; Karl, IE; Osborne, DF; Wegrzyn, LE, 1996
)
0.29
" These measurements include dose-response of alanine at 140 MeV, and comparison of response vs energy with a parallel plate ionization chamber."( Alanine EPR dosimeter response in proton therapy beams.
Bensen, D; Desrosiers, M; Gall, K; Serago, C,
)
0.13
" No evidence of tolerance to anti-MES activity after repeated dosing was observed."( Preclinical evaluation of PNU-151774E as a novel anticonvulsant.
Bonsignori, A; Cervini, MA; Fariello, RG; Maj, R; Marrari, P; McArthur, RA; Pevarello, P; Post, C; Salvati, P; Varasi, M; White, HS; Wolf, HH; Woodhead, JW, 1998
)
0.3
" Sixty patients received 40 mg of omeprazole twice a day, 1500 mg of amoxicillin three times a day, and 300 mg of rebamipide three times a day (group OAR); the other 60 patients received the same dosage of omeprazole and amoxicillin but no rebamipide for two weeks (group OA)."( Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.
Ando, K; Arakawa, T; Harihara, S; Higuchi, K; Ito, H; Kobayashi, K; Kuroki, T; Nebiki, H; Uchida, T, 1998
)
0.3
" In conclusion, this study suggests that short-term administration of LA at high dosage to normal and diabetic rats causes an inhibition of gluconeogenesis secondary to an interference with hepatic fatty acid oxidation."( Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats.
Bashan, N; Gutman, A; Khamaisi, M; Potashnik, R; Rudich, A; Tritschler, HJ, 1999
)
0.3
" Depending on the degree of the precipitation, which was dosage dependent, and the location, which differed somewhat between the two compounds, the lesions varied from acute obstruction with tubule cell necrosis, nephron dilation, and sudden death with no inflammation to severe chronic pyogranulomatous inflammation."( Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney.
Cortez, E; Fouant, M; Friedman, RM; Hribar, J; Khan, N; Levin, S; Nicholas, M; Schlessinger, S,
)
0.13
" Similar evidence for PDH activation was demonstrated at 2 and 24 h after dosing in both tissues."( Biochemical and neurotoxicological effects of L-2-chloropropionic acid on rodent brain.
Bachelard, HS; Jones, P; Lock, EA; Williams, RE, 1999
)
0.3
" However, it was not possible to generate dose-response curves whereas significant correlations of uptake values with T50 values were found."( The effect of oxytocin, prostaglandin E2 and acetylsalicylic acid on flow distribution and on the transfer of alanine, glucose and water in isolated perfused guinea pig placentae.
Goepel, E; Niemax, K; Rybakowski, C; Schröder, HJ, 2000
)
0.31
"Pharmacokinetic responses to oral doses of the dipeptide, L-alanyl-glutamine (Ala-Gln), were evaluated after a single, bolus load or an intermittent dosing in normal healthy subjects (n = 8) to find the optimal mode of oral administration."( The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever.
Fürst, P; Klassen, P; Mazariegos, M; Solomons, NW, 2000
)
0.31
" Animals dosed with RB 120 (10 mg/kg) failed to develop a discriminative response."( Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties.
Fournié-Zaluski, M; Hutcheson, DM; Maldonado, R; Pache, DM; Roques, BP; Sewell, RD; Subhan, F, 2000
)
0.31
" Oral GP IIb/IIIa inhibitors have been associated with an increased incidence of bleeding, but additional experience may permit the design of dosing regimens that decrease this risk."( Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Cannon, CP, 2000
)
0.31
" The competitive antagonistic action was further confirmed by the finding that rebamipide caused a parallel shift to the right in the dose-response curve of O2 production induced by fMLP."( Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils.
Azuma, A; Imagawa, K; Ishiyama, H; Kikuchi, M; Nagano, C; Sekiguchi, K, 2001
)
0.31
" We show that the requirement for the Ceg1-binding domain of Cet1 for yeast cell growth can be circumvented by overexpression in high gene dosage of a catalytically active mutant lacking the Ceg1-binding site (Cet1(269-549)) provided that Ceg1 is also overexpressed."( An essential function of Saccharomyces cerevisiae RNA triphosphatase Cet1 is to stabilize RNA guanylyltransferase Ceg1 against thermal inactivation.
Hausmann, S; Ho, CK; Schwer, B; Shuman, S, 2001
)
0.31
" Given the considerably higher infusion volumes that will be entailed in the delivery of BPA in the new high dosage protocols, there will be a requirement to extend the gap between fractions to 2 or more days."( Boron neutron capture therapy: effects of split dose and overall treatment time.
Coderre, JA; Hopewell, JW; Micca, PL; Morris, GM; Rezvani, M, 2001
)
0.31
" The inhibition of (+)-leader RNA and mRNA synthesis by wt C proteins (nonfusion) showed nearly identical dose-response curves, suggesting that inhibition occurs early in RNA synthesis."( Sendai virus wild-type and mutant C proteins show a direct correlation between L polymerase binding and inhibition of viral RNA synthesis.
Grogan, CC; Moyer, SA, 2001
)
0.31
" Nevertheless, none of these fibans was able to effectively block shear-induced platelet adhesion at targeted clinical dosing regimens except for abciximab."( Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X, 2002
)
0.31
"The discovery of a functional single-nucleotide polymorphism in the cyclooxygenase 1 locus may ultimately improve the safe and effective use of acetylsalicylic acid by better tailoring of dosage with an individual's genetic variation."( Genetic variation in cyclooxygenase 1: effects on response to aspirin.
Halushka, MK; Halushka, PV; Walker, LP, 2003
)
0.32
" Site occupancy studies combined with clot retraction experiments addressed whether high affinity and slow off-rate compounds can alter clot retraction during the dosing interval."( Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
Billheimer, JT; He, B; Kieras, CJ; Pedicord, DL; Seiffert, D; Stern, AM, 2002
)
0.31
" While the biphenyltetrazole compound candesartan dissociated slowly and behaved as an insurmountable antagonist for WT-AT(1), it dissociated swiftly and only produced a rightward shift of the angiotensin Ang II- and -IV dose-response curves for inositol phosphate (IP) accumulation in cells expressing N111G."( Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors.
Hunyady, L; Kersemans, V; Le, MT; Szaszák, M; Vanderheyden, PM; Vauquelin, G, 2003
)
0.32
" In order to examine dosage dependency in the effect of MTPG, 4 dosages of MTPG (0."( [Effects of alpha-methyl-(4-tetrazolyl-phenyl) glycine on the induction of hippocampal ischemic tolerance in the rat].
Ai, J; Chen, XL; Feng, RF; Li, QJ; Li, WB; Liu, HQ; Zhao, HG; Zhou, AM, 2003
)
0.32
" Fluvoxamine was administered for 6 weeks with a specific dosage plan (50-200 mg/day) in 66 Japanese major depressive patients."( Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine.
Higuchi, H; Inoue, K; Ito, K; Itoh, K; Kamata, M; Naito, S; Ohkubo, T; Sato, K; Shimizu, T; Suzuki, T; Takahashi, H; Yoshida, K, 2003
)
0.32
" The contributions of the metabolites to the separation of control from dosed liver tissues varied depending on the type of spectral editing method used."( Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues.
Antti, H; Beckonert, O; Bollard, ME; Ebbels, TM; Holmes, E; Keun, H; Lindon, JC; Nicholson, JK; Tang, H; Wang, Y, 2003
)
0.32
" These mGluRs are functionally active on catecholamine (CA) secretion in chromaffin cells because both (1S, 3R)-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) and the specific agonist of Group I mGluRs, (S)-3,5-dihydroxyphenylglycine (DHPG), were able to stimulate the release of CAs (adrenaline and noradrenaline) in a dose-response manner."( Expression and functional properties of group I metabotropic glutamate receptors in bovine chromaffin cells.
Aránguez, I; Arce, C; Del Campo, AB; Figueroa, S; González, MP; López, E; Oset-Gasque, MJ, 2004
)
0.32
" Second messenger generation by the TPbeta-Y339A and TPbeta-I343A mutants was drastically reduced compared to the wild-type receptor as suggested by dose-response and time-course experiments of inositol phosphates production following agonist treatment, despite normal coupling between the receptors and the Galpha(q) protein."( Role of the Rab11-associated intracellular pool of receptors formed by constitutive endocytosis of the beta isoform of the thromboxane A2 receptor (TP beta).
Parent, JL; Rochdi, MD; Thériault, C, 2004
)
0.32
" Urine samples were collected daily for 9 days from both dosed and control animals."( A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity.
Bright, J; Knight, R; Lenz, EM; Major, H; Wilson, ID, 2004
)
0.32
" Reduced dosage of CTK1 rescued the growth defect of ess1(ts) mutants, while overexpression of CTK1 enhanced the growth defects of ess1(ts) mutants."( Genetic interactions with C-terminal domain (CTD) kinases and the CTD of RNA Pol II suggest a role for ESS1 in transcription initiation and elongation in Saccharomyces cerevisiae.
Hanes, SD; Rossettini, A; Wilcox, CB, 2004
)
0.32
" Because 30% of panipenem and most of the betamipron are excreted in the urine in an unchanged form, renal function is the important determinant of the dosage regimen of panipenem/betamipron."( Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005
)
0.33
" Accordingly, when all the data for the dose-response curve and time course were correlated, a strong association was observed between the brain and CSF Abeta(40) levels."( Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-di
Atack, JR; Best, JD; Ellis, S; Harrison, T; Jay, MT; Lewis, HD; Ma, J; Nadin, A; Otu, F; Pattison, C; Reilly, M; Shearman, MS; Williamson, TL, 2005
)
0.33
" H-89, per se, did not modify glutamate release but reduced extracellular GABA value at the higher dosage used (200 microM)."( Differential roles of mGlu8 receptors in the regulation of glutamate and gamma-aminobutyric acid release at periaqueductal grey level.
de Novellis, V; Maione, S; Marabese, I; Mariani, L; Palazzo, E; Rodella, L; Rossi, F; Siniscalco, D, 2005
)
0.33
" The dose-response coefficient, K(dr) of sc-alanine dosimeters was stable in all investigated dose range from 1 to 23 kGy."( Solid state "self-calibrated" EPR-dosimeters-advantageous and shortcomings.
Fabisiak, S; Peimel-Stuglik, Z, 2006
)
0.33
" The relevance of circadian dosing time was investigated for chronotherapeutic optimization of SDX-102."( Circadian pharmacology of L-alanosine (SDX-102) in mice.
Carrière, J; Crépin, D; Elliott, G; Guettier, C; Kanekal, S; Lévi, F; Li, XM, 2006
)
0.33
"Electron Paramagnetic Resonance (EPR) study of irradiated l-alanine showed differences in dose-response curves obtained at low and high microwave power for a broad range of doses, up to 3000 kGy."( Combined effects of high doses and temperature on radiation-induced radicals and their relative contributions to EPR signal in gamma-irradiated alanine.
Ciesielski, B, 2006
)
0.33
" Even though Cys and its oxidized product (cystine) are equally efficacious at levels at or below their dietary requirements for maximal growth, Cys is far more toxic than cystine when administered orally in the pharmacologic dosing range."( Comparative species utilization and toxicity of sulfur amino acids.
Baker, DH, 2006
)
0.33
"Although plasma concentrations of panipenem were elevated and the risk of adverse events would increase in patients with renal impairment, a precise dosage regimen for patients with renal impairment has not been established."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
" Optimal dosage regimens for patients with renal impairment were determined based on the bacteriostatic index of C(20%T)>(MIC), the concentration corresponding to the time above MIC of 20% of the dosing interval."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
"The dosage regimen of panipenem for patients with renal impairment should be reduced when creatinine clearance is lower than 60 ml/min."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
" These studies demonstrate that the 3- to 5-fold therapeutic window for LY411,575 can be exploited to obtain reduction in Abeta levels without induction of intestinal side effects, that intermittent treatment could be used to mitigate side effects, and that a 6-day dosing paradigm can be used to rapidly determine the therapeutic window of novel gamma-secretase inhibitors."( Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Bara, T; Chen, J; Clader, JW; Higgins, GA; Hyde, LA; Josien, H; Manfra, D; McHugh, NA; Nomeir, AA; Parker, EM; Zhang, L; Zhang, Q, 2006
)
0.33
" Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential."( Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P, 2006
)
0.33
"Our results strongly suggest an association between the Ala54Thr polymorphism of FABP2 with diabetes, revealing a genetic dosage effect regarding its association with diabetes in Chilean elders."( FABP2 Ala54Thr polymorphism and diabetes in Chilean elders.
Albala, C; Angel, B; Lera, L; Liberman, C; Pérez-Bravo, F; Sanchez, H; Santos, JL; Villarroel, A, 2007
)
0.34
"Twenty patients with the active distal type of UC in whom corticosteroid treatment had been unsuccessful were treated with rectal administration of Rebamipide twice a day for 3 weeks, during which corticosteroid dosage was kept constant."( Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis.
Ando, T; Furuta, R; Goto, H; Ina, K; Ishiguro, K; Kusugami, K; Maeda, O; Watanabe, O, 2007
)
0.34
" Chronic dosing of BMS-433796 in Tg2576 mice suggested a narrow therapeutic window and Notch-mediated toxicity at higher doses."( Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheime
Barten, DM; Bergstrom, C; Corsa, JA; Dangler, C; Gao, Q; Guss, VL; Hendrick, JP; Loo, A; Polson, CT; Prasad, CV; Roberts, SB; Robertson, BJ; Sleczka, BG; Smith, DW; Vig, S; Wang, J; Yeola, S; Zheng, M, 2007
)
0.34
" Enemas containing 150 mg rebamipide per dosing were administered after morning bowel movement, and always prior to bedtime, twice daily for 4 weeks."( Rebampide enema therapy as a treatment for patients with chronic radiation proctitis: initial treatment or when other methods of conservative management have failed.
Cho, M; Heo, J; Kang, DH; Kim, GH; Kim, TO; Lee, SM; Song, GA, 2008
)
0.35
" In a dose-response setting in immunocompetent mice maximum bactericidal effects (10,000 times reduction) of intravenously injected (99m)Tc-hLF 1-11 was seen with 40 mg/kg whereas the same dose of orally administered (99m)Tc-hLF 1-11 induced about approximately 100 times reduction."( Various routes of administration of (99m)Tc-labeled synthetic lactoferrin antimicrobial peptide hLF 1-11 enables monitoring and effective killing of multidrug-resistant Staphylococcus aureus infections in mice.
Brouwer, CP; Welling, MM, 2008
)
0.35
" The colonic and plasma concentrations were analyzed by high performance liquid chromatography (HPLC) to evaluate colon-targeting action after oral administration of various dosage forms, and rebamipide with absorption enhancers in chitosan dosage forms."( Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier.
Akira, Y; Duan, L; Huang, BB; Li, GF; Luo, JH; Nobuaki, K, 2008
)
0.35
" In addition, we describe acute effect of CS-917 on fasting hyperglycemia in overnight-fasted GK rats and chronic effect of CS-917 in multiple dosing GK rats."( CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Fujiwara, T; Hagisawa, Y; Izumi, M; Ohsumi, J; Okuno, A; Takahashi, K; Yoshida, T, 2008
)
0.35
" water speed and volume (both variables determining flow boundary stress in the shear device), formulation dosage and drying temperature, was set up to monitor colloid detachment."( Detachment of sprayed colloidal copper oxychloride-metalaxyl fungicides by a shallow water flow.
López-Periago, JE; Paradelo-Pérez, M; Pose-Juan, E; Rial-Otero, R; Simal-Gándara, J, 2009
)
0.35
" Average losses for metalaxyl and copper oxychloride were, respectively, 29 and 50% of the quantity applied at the usual recommended dosage for crops."( Detachment of sprayed colloidal copper oxychloride-metalaxyl fungicides by a shallow water flow.
López-Periago, JE; Paradelo-Pérez, M; Pose-Juan, E; Rial-Otero, R; Simal-Gándara, J, 2009
)
0.35
" Results from this approach can assist in making decisions about drug dosing and frequency in the design of larger and longer clinical trials for diseases such as Alzheimer's disease, and may accelerate effective drug validation."( A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
Bateman, RJ; Browning, KR; Demattos, RB; Friedrich, SW; Holtzman, DM; Mawuenyega, KG; May, PC; Paul, SM; Siemers, ER; Sigurdson, WC; Wen, G; Yarasheski, KE, 2009
)
0.35
" In contrast, significant reduction of 40-50% of interstitial fluid Abeta and wildtype cortical Abeta was observed when infusing LY2434074 directly into the brain by means of reverse microdialysis or by dosing the BACE1 inhibitor to p-glycoprotein (p-gp) mutant mice."( Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Bastlund, JF; Elvang, AB; Jensen, KG; Karlsson, JJ; Larsen, SA; Mørk, A; Pedersen, LØ; Stensbøl, TB; Volbracht, C, 2009
)
0.35
"4-dihydroxyphenyl)methylene glycine hydrazide (GlyH-101) and glibenclamide and their dose-response effect was investigated."( Electrophysiological characterization of electrolyte and nutrient transport across the small intestine in horses.
Breves, G; Burmester, M; Cehak, A; Feige, K; Geburek, F, 2009
)
0.35
" In normal rats, Michaelis-Menten kinetics were able to describe the dose-response of the fitted exchange rate constants with a 13."( Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice.
Albers, MJ; Bok, R; Chen, AP; Hurd, RE; Kurhanewicz, J; Nelson, SJ; Park, I; Tropp, J; Vigneron, DB; Yen, YF; Zhang, V; Zierhut, ML, 2010
)
0.36
" Vital signs (temperature, blood pressure, and heart rate) were measured before and after dosing in both periods."( Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
Cho, HY; Lee, YB; Park, GK; Yoon, H, 2009
)
0.35
" Aiming to assess gamma/thermal neutrons dose from research reactors, Fricke gel and alanine gel solutions produced at IPEN using 300 bloom gelatin were mixed with Na(2)B(4)O(7) salt, and the mixtures were irradiated at the beam hole #3 of the IEA-R1 research reactor, (BH#3) adapted to BNCT studies, and the dose-response was evaluated using spectrophotometry technique."( Gamma/neutron dose evaluation using Fricke gel and alanine gel dosimeters to be applied in boron neutron capture therapy.
Campos, LL; Coelho, PR; Mangueira, TF; Silva, CF,
)
0.13
" When placed within Saccharomyces cerevisiae G alpha subunit Gpa1, the fast-hydrolysis mutation restored appropriate dose-response behaviors to pheromone signaling in the absence of RGS-mediated GAP activity."( Regulators of G-protein signaling accelerate GPCR signaling kinetics and govern sensitivity solely by accelerating GTPase activity.
Cappell, SD; Johnston, CA; Kimple, AJ; Kuravi, S; Lambert, NA; Siderovski, DP; Willard, FS, 2010
)
0.36
" In the present study, 9 dogs were treated with a single dose of the γ-secretase modulator E2012, the γ-secretase inhibitor LY450139, or vehicle with a dosing interval of 1 week."( Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Andreasson, U; Blennow, K; Borghys, H; Gustavsson, MK; Mercken, M; Portelius, E; Van Broeck, B; Zetterberg, H, 2010
)
0.36
" The population pharmacokinetic model was used to predict exposure of the active moiety R-125338 and thus to identify potential CS-917 dosage reduction criteria."( Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites.
Carrothers, TJ; Habtemariam, B; Kastrissios, H; Khariton, T; Kshirsagar, S; Mager, DE; Rohatagi, S; Walker, JR, 2012
)
0.38
" Two single-dose (140 mg), open-label, randomized, 3-period, crossover studies evaluated the effect of formulation, food, and time of dosing on the pharmacokinetics and pharmacodynamics of semagacestat in healthy participants."( Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
Annes, WF; Ayan-Oshodi, M; de la Peña, A; Friedrich, S; Lowe, SL; Sirois, PJ; Willis, BA; Zhang, W, 2012
)
0.38
"After taking into account the physiochemical properties of RBM (solubility, melting point, dosage etc."( Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.
Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Tung, NT, 2011
)
0.37
" Joint analysis of rs1801282-C, rs1063539-G, and rs1884614-T risk alleles showed an additive dosage effect (P for trend=0."( Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population.
Chan, JC; Germer, S; Ho, JS; Ma, RC; Martin, M; Ng, MC; So, WY; Tam, CH, 2012
)
0.38
"This randomized, double-blind, placebo-, comparator (selegiline 10 mg/day)-, and positive (phenelzine 30 mg/day)-controlled study investigated the pressor response to oral tyramine under fasting conditions after the administration of safinamide at therapeutic (100 mg/day) and supratherapeutic (350 mg/day) dosing regimens in healthy volunteers for the purpose of assessing the need for dietary restrictions."( The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A, 2012
)
0.38
"A randomized, double-masked, multicenter, placebo-controlled, parallel-group, dose-response phase II study."( Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2012
)
0.38
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."( Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013
)
0.39
" This may translate into greater antiviral efficacy, a higher barrier to resistance, and an improved safety profile relative to TDF, supporting further investigation of TAF dosed once daily in HIV-infected patients."( Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013
)
0.39
"4) weeks when study drug dosing was halted."( Adverse events and dropouts in Alzheimer's disease studies: what can we learn?
Henley, DB; Schneider, LS; Sethuraman, G; Sundell, KL, 2015
)
0.42
" The grade of gastric mucosal injuries was evaluated by esophagogastroduodenoscopy before and after dosing (on day 0 and day 14), and the grade of gastric mucosal injury was assessed according to the modified Lanza score."( A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel.
Fukui, H; Hida, N; Hori, K; Miwa, H; Nakamura, S; Ogawa, T; Ohda, Y; Okugawa, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J, 2014
)
0.4
" The proposed methods have been successfully applied to the analysis of REB in pharmaceutical dosage forms without interference from other dosage form excipients."( Stability-indicating determination of rebamipide in the presence of its acid degradation products.
Abbas, SS; El-Bardicy, MG; Essam, HA; Zaazaa, HE,
)
0.13
" At harvest, pepper samples were found to contain metalaxyl and cymoxanil well below the maximum residue limit MRLs of the European Union (EU) following the recommended dosage and the interval of 21 days after last application."( Dissipation and residue of metalaxyl and cymoxanil in pepper and soil.
Cui, Y; Hu, D; Li, X; Li, Z; Liu, X; Yang, Y; Zhang, K; Zhu, H, 2014
)
0.4
" The optimized RBM-SD was formulated in tablet dosage form, containing approximately 2 % sodium lauryl sulphate and poloxamer F68 as wetting agents."( Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability.
Choi, HG; Choi, IS; Choi, JY; Kim, JO; Pradhan, R; Tran, TH; Yong, CS, 2015
)
0.42
" Adherence to the dosing regimen has emerged as a critical factor determining efficacy outcomes of clinical trials."( Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
Baum, MM; Beliveau, M; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Remedios-Chan, M; Smith, TJ; Yang, F, 2015
)
0.42
"Rats were given either vehicle or rebamipide (30 mg/kg) orally twice daily for two days, then on the third day respective groups were dosed with either vehicle, celecoxib (40 mg/kg), or diclofenac (10 mg/kg) in addition to a respective dose of vehicle or rebamipide."( Celecoxib or diclofenac hepatic status in the presence or absence of rebamipide.
Denham, JW; Harirforoosh, S; Murrell, DE; Panus, PC; Rahmasari, Y, 2015
)
0.42
" There was a significantly positive dose-response association between SUA levels and the prevalence of elevated ALT."( Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population.
Chen, S; Guo, X; Li, Z; Sun, G; Sun, Y; Yang, H; Yu, S, 2016
)
0.43
" When dosed once-daily, TAF results in approximately 90% lower levels of plasma TFV and a 4-fold increase in intracellular TFV-diphosphate (TFV-DP) in PBMCs compared with the TFV prodrug tenofovir disoproxil fumarate (TDF)."( Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
Babusis, D; Callebaut, C; Kitrinos, K; Liu, Y; Miller, M; Ray, A, 2017
)
0.46
" The pretreatment period, dosing frequency, and dose dependency of rebamipide were examined."( Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats.
Nakashima, T; Sakurai, K; Uematsu, N, 2017
)
0.46
"After tenofovir alafenamide dosing in vivo , tenofovir-dp was unquantifiable in most tissues (91%) although cervical and vaginal epithelial cells efficiently formed tenofovir-dp from tenofovir alafenamide in vitro ."( Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.
Cottrell, ML; Emerson, CW; Garrett, KL; Gay, C; Kashuba, ADM; McCallister, S; Peery, A; Prince, HMA; Rooney, JF; Schauer, A; Sykes, C, 2017
)
0.46
" Developing efficient nanodrugs could reduce the dosage and greatly improve the therapeutic effects in cancer treatments."( Amino acid functionalized gadofullerene nanoparticles with superior antitumor activity via destruction of tumor vasculature in vivo.
Deng, R; Guan, M; Guo, J; Jia, W; Li, J; Li, X; Lu, Z; Shu, C; Sun, L; Wang, C; Yu, T; Zhang, Y; Zhen, M; Zhou, Y; Zou, T, 2017
)
0.46
" A significant dose-response effect between (R, S)-benalaxyl and global methylation level was observed."( Acylamino acid chiral fungicides on toxiciepigenetics in lambda DNA methylation.
Chang, J; Guo, B; Hao, W; Wang, H; Xu, Q; Yin, J; Zhu, F, 2017
)
0.46
" Safinamide will help to reduce dosing of levodopa but also of dopamine agonists during long term treatment in patients with Parkinson's disease."( Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller, T, 2017
)
0.46
" Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity."( Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.
Burgess, KE; Clifford, CA; Fan, TM; Morges, MA; Phillips, B; Saba, CF; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2018
)
0.48
" Effective rabies antivirals for therapeutic use need to be molecules that can be dosed into the cerebrospinal fluid and that rapidly and potently block ongoing virus replication and as such stop the further spread of the virus."( The path towards effective antivirals against rabies.
Jochmans, D; Neyts, J, 2019
)
0.51
" Areas covered: The favourable pharmacological profile of TAF allows a marked reduction in dosage (25 mg/day) thus reducing systemic exposure to tenofovir and improving the bone and renal safety, keeping however the same virological efficacy, compared to TDF 300 mg/day."( Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018
)
0.48
" Using a murine model, we compared the plasma and tissue pharmacokinetics of TFV and various TFV prodrugs, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and hexadecyloxypropyl tenofovir (CMX157), after dosing as enema formulations with varying osmolality and ion content."( Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW, 2019
)
0.51
"The goal of this work was to evaluate dosing strategies for tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) with injection drug use with a pharmacokinetic/pharmacodynamics analysis of concentration data generated from two single-dose clinical studies conducted in healthy women."( A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018
)
0.48
" At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h)."( Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM, 2019
)
0.51
"High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention."( Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A, 2019
)
0.51
"Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error)."( Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Ahmed, S; Asperges, E; Bernett, J; Brainard, DM; Cao, H; Castagna, A; Chelliah, D; Chen, D; Chihara, S; Childs, R; Chokkalingam, A; Cohen, SH; Cunningham, J; D'Arminio Monforte, A; Desai, P; DeZure, A; Diaz, G; Elboudwarej, E; Feldt, T; Flanigan, T; Gaggar, A; Green, G; Green, ML; Grein, J; Henne, I; Ismail, S; Kato, H; L'Her, E; Lapadula, G; Lescure, FX; Maeno, T; Majumder, S; Massari, M; Mera, R; Mora-Rillo, M; Mutoh, Y; Myers, RP; Nguyen, D; Nicastri, E; Oda, R; Ohmagari, N; Osinusi, AO; Quiros-Roldan, E; Redinski, J; Sellers, S; Shin, D; Studemeister, A; Tan, SK; Telep, L; Timbs, L; Verweij, E; Winterbourne, L; Yo, K; Zhao, Y; Zhong, L; Zoufaly, A, 2020
)
0.56
" AEs were most commonly of gastrointestinal origin (hyporexia/diarrhoea) and generally resolved with supportive treatment and/or dosage adjustment."( Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z, 2020
)
0.56
"\ Conclusions: The patients were generally satisfied with the change in medication and well nformed about the dosage and advantages of TAF over TDF, but less well informed about the possible adverse effects of TAF."( Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M, 2020
)
0.56
" To support pediatric clinical studies for investigational treatments of coronavirus disease 2019 (COVID-19), pediatric-specific dosing is required."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"To define pediatric-specific dosing regimens for hydroxychloroquine and remdesivir for COVID-19 treatment."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
" Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
" A simulation-based dose-ranging study was conducted in simulated children exploring different absolute and weight-normalized dosing strategies."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"For hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"This analysis provides pediatric-specific dosing suggestions for hydroxychloroquine and remdesivir and raises concerns regarding hydroxychloroquine use for COVID-19 treatment because concentrations were less than those needed to mediate an antiviral effect."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg)."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020
)
0.56
" Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020
)
0.56
" Remdesivir was dosed intravenously at 200 mg on day 1 followed by 100 mg/d."( Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Ahn, MY; Arribas López, JR; Bernasconi, E; Bhagani, S; Blair, C; Brainard, DM; Cao, H; Castagna, A; Cattelan, AM; Chai, LYA; Chang, SC; Criner, GJ; Gaggar, A; Gottlieb, RL; Huhn, G; Hyland, RH; Le Turnier, P; Malhotra, P; Marty, FM; McPhail, MJ; Mullane, KM; Ogbuagu, O; Osinusi, AO; Roestenberg, M; Sanyal, AJ; SenGupta, D; Soriano Viladomiu, A; Spinner, CD; Tsang, OTY; Wang, H, 2020
)
0.56
" The known association between ACPA level and alanine at position 74 of HLA-DRβ1 in ACPA-positive RA was revisited to understand the phenotypic effect of allele-specific expression of HLA-DRB1 by modeling multivariate logistic regression with the genomic dosage or relative expression dosage of Ala-74 in 2 independent sets of 1,723 Korean RA patients with ACPA."( Allele-Specific Quantification of HLA-DRB1 Transcripts Reveals Imbalanced Allelic Expression That Modifies the Amino Acid Effects in HLA-DRβ1.
Bae, SC; Bang, SY; Chun, S; Cui, J; Gu, KN; Ha, E; Kim, K; Lee, HS, 2021
)
0.62
" The association between HLA-DRβ1 Ala-74 and ACPA level in RA was better explained by relative expression dosage of Ala-74 than by the genomic dosage (change in Akaike's information criterion = -6."( Allele-Specific Quantification of HLA-DRB1 Transcripts Reveals Imbalanced Allelic Expression That Modifies the Amino Acid Effects in HLA-DRβ1.
Bae, SC; Bang, SY; Chun, S; Cui, J; Gu, KN; Ha, E; Kim, K; Lee, HS, 2021
)
0.62
" Therapies dosed soon after peak viral load when symptoms develop may decrease shedding duration and immune response intensity but have little effect on viral area under the curve (AUC), which is driven by high early viral loads."( Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.
Cardozo-Ojeda, EF; Goyal, A; Schiffer, JT, 2020
)
0.56
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."( Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Govil, A; Luckett, K; Miller-Handley, H, 2020
)
0.56
" Recommendations were made based on available data, consideration of pharmacokinetic properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known toxicities."( Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Back, D; Boyle, A; Burger, D; Davidson, K; El-Sherif, O; Gibbons, S; Khoo, S; Marra, F; Marzolini, C; Siccardi, M; Smolders, EJ; Sommerville, AJ, 2021
)
0.62
"In this study, a green stability indicating chromatographic methods were developed and validated for the quantitative determination of tenofovir alafenamide in the presence of its degradation products in bulk powder as well as in dosage forms."( Assessment of the greenness of new stability indicating micellar UPLC and HPTLC methods for determination of tenofovir alafenamide in dosage forms.
Abdel-Razeq, SA; Nasr, ZA; Said, NS, 2021
)
0.62
" As opposed to intravenous injection, extended release subcutaneous injection has the benefits of reducing face-to-face contact, minimizing hospitalization, reducing dosing frequency and reducing overall health care cost."( Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment.
Palekar, S; Patel, K; Patki, M; Reznik, S, 2021
)
0.62
" However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence."( COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Berkman, SA; Tapson, VF, 2021
)
0.62
" We describe utilizing the recall antigen assay platform to screen small molecule drug off-target effects on memory T cell expansion/function using a dosing regimen based on adenosine treatment."( Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells.
Daftarian, PM; George, MV; Kleiman, E; Magcase, D; Mao, B; Sierra, G, 2021
)
0.62
" Frequent dosing is therefore required, which needs expert personnel and multiple hospital visits and can result in serious side effects."( Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment
Kunda, NK; Patel, K; Patil, SM; Patki, M; Saraswat, A; Vartak, R, 2021
)
0.62
" TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks."( Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022
)
0.72
" These methods are useful for analysis of REB in pharmaceutical dosage form."( Development and Validation of Four Spectrophotometric Methods for Assay of Rebamipide and its Impurity: Application to Tablet Dosage Form.
Alqarni, MA; El Ghobashy, MR; Farid, NF; Moatamed, RS; Naguib, IA, 2022
)
0.72
" No studies have yet compared TFV-DP in PBMC from lower than daily dosing between prodrugs, which has potential implications for event-driven preexposure prophylaxis and pharmacologic forgiveness."( Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL, 2021
)
0.62
"HIV-negative adults were randomized to two 12-week DOT regimens of 33, 67 or 100% of daily dosing with emtricitabine (F)/TAF 200 mg/25 mg (TAF-DBS) or F/TDF 200 mg/300 mg (DOT-DBS), separated by a 12-week washout."( Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL, 2021
)
0.62
" Low-dose radiation (LDR), at a much lower dosage than applied in cancer treatment, re-emerged after a 75-year silence in its use in unresolved pneumonia, as a scientific interest with surprising effects in soothing the cytokine storm and other symptoms in severe COVID-19 patients."( COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation.
Azzam, EI; Jadhav, AB; Wang, Y; Yu, J, 2021
)
0.62
" These predictions along with the organ impairment study results may be used to support decision making regarding the RDV dosage adjustment in these patient subgroups."( Whole Body PBPK Modeling of Remdesivir and Its Metabolites to Aid in Estimating Active Metabolite Exposure in the Lung and Liver in Patients With Organ Dysfunction.
Arya, V; Earp, JC; Fan, J; Grimstein, M; Kitabi, E; Reynolds, KS; Wang, Y; Yang, Y; Zhang, X; Zhu, H, 2022
)
0.72
" Its clinical efficacy has been evaluated, but needs to be optimized with regard to timing, dosage and duration of treatment, and route of administration."( Remdesivir: Quo vadis?
De Clercq, E, 2021
)
0.62
" We found that mean (standard deviation) recovery of RDV at 6 hours after dosing was low in both the ECMO (33."( Remdesivir and GS-441524 Extraction by Ex Vivo Extracorporeal Life Support Circuits.
Green, DJ; Imburgia, CE; Kelley, WE; Mcknite, AM; Reilly, CA; Rower, JE; Watt, KM, 2022
)
0.72
"This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B)."( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021
)
0.62
" Inhalation RDV dosing resulted in lower systemic exposures to RDV and its metabolites as compared with IV RDV dosing."( Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection.
Babusis, D; Bannister, R; Bilello, JP; Cihlar, T; Ellis, S; Gigliotti, A; Hartke, J; Irshad, H; Kadrichu, N; Kim, C; Kuehl, PJ; Lee, WA; Ma, B; Mackman, RL; Murakami, E; Niu, C; Pitts, J; Porter, DP; Rautiola, D; Seigel, D; Smith, B; Subramanian, R; Tomkinson, A; Vermillion, MS; Yang, J; Zhao, X, 2022
)
0.72
" Tenofovir is an important component of management, but the associated risk of nephrotoxicity makes dosing a challenge in patients with impaired kidney function."( Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa.
Barday, Z; Geragotellis, A; Naicker, V; Patel, S; Sanglay, L; Sonderup, M; Spearman, CW; Wearne, N, 2022
)
0.72
" Unexpectedly, despite enhanced dissolution rate in a controlled manner, a designed bilayer tablet had no dose- and dosage form dependent in vivo bioavailability in beagle dogs as compared with IR 100 mg RBM reference tablet."( Design and evaluation of in vivo bioavailability in beagle dogs of bilayer tablet consisting of immediate release nanosuspension and sustained release layers of rebamipide.
Cao, QR; Cui, JH; Jin, G; Jung, M; Lee, BJ; Ngo, HV; Park, C; Wang, J, 2022
)
0.72
" Systemic drug disposition during TAF implant dosing was explained by a multi-compartment pharmacokinetic (PK) model."( Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
Baum, MM; Beliveau, M; Buser, C; Caprioli, RM; Castonguay, AE; Gallay, PA; Gunawardana, M; Hendrix, CW; Kuo, J; Marzinke, MA; Moss, JA; Remedios-Chan, M; Reyzer, ML; Sanchez, D; Trinh, M; Tuck, M; Webster, P; Webster, S, 2022
)
0.72
" Alternative dosing regimens were evaluated using Monte Carlo simulations."( Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
Bosma, LBE; Leegwater, E; Moes, DJAR; Ottens, TH; van der Meer, IM; van Nieuwkoop, C; Wilms, EB, 2022
)
0.72
" Our existing PK model, supported by an intravenous (IV) dosing dog study, was adapted to analyze mechanistic aspects underlying implant TAF delivery."( Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Baum, MM; Beliveau, M; Fanter, R; Gallay, PA; Gunawardana, M; Kuo, J; Marzinke, MA; Moss, JA; Ramirez, CM; Remedios-Chan, M; Sanchez, D; Trinh, M; Webster, P; Webster, S, 2023
)
0.91
"A comparative investigation of amino acids (proline, cysteine, and alanine) as dosimetric materials using electron paramagnetic resonance (EPR) spectroscopy in the absorbed dosage range of 1-25 kGy is presented."( Application of Amino Acids for High-Dosage Measurements with Electron Paramagnetic Resonance Spectroscopy.
Karakirova, Y, 2023
)
0.91
" However, considering its rapid uptake into target cells, we suggest only a cautious increase of tenofovir alafenamide dosage intervals to 2 or 3 days only in case of moderate or severe CKD, respectively."( Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P, 2023
)
0.91
" AUC in the dosing interval at steady state was 13,150 and 23,100 ng • h/mL for 50 and 100 mg of safinamide."( Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers.
Cattaneo, C; Jing, S; Leuratti, C; Vaja, V; Yuan, Y, 2023
)
0.91
" On 3 dpi, one group received a loading dose of 10 mg/kg remdesivir followed by daily dosing with 5 mg/kg for 11 days, one group received 10 mg/kg on 12 consecutive days, and the remaining group received an equivalent volume of vehicle solution."( Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection.
Bunyan, E; Cihlar, T; de Wit, E; Feldmann, F; Feldmann, H; Goldin, K; Lo, MK; Lovaglio, J; Okumura, A; Porter, DP; Saturday, G; Spiropoulou, CF; Williamson, BN, 2023
)
0.91
" coli HNIQLE-AlaDH expressing ω-transaminase from Aspergillus terreus and alanine dehydrogenase from Bacillus subtilis was firstly used aminate lignin-derived vanillin to vanillylamine by using a relatively low dosage of amine donors (vanillin:L-alanine:isopropylamine = 1:1:1, mol/mol/mol)."( Biological valorization of lignin-derived vanillin to vanillylamine by recombinant E. coli expressing ω-transaminase and alanine dehydrogenase in a petroleum ether-water system.
Chai, H; He, YC; Li, L; Ma, C, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (9 Items)

ItemProcessFrequency
Groceriescore-ingredient2
Salad dressingscore-ingredient2
Saucescore-ingredient2
Condimentscore-ingredient2
supliment alimentarcore-ingredient1
Snackscore-ingredient1
en:open-beauty-factscore-ingredient1
Whey powdercore-ingredient1
Dairiescore-ingredient1

Roles (2)

RoleDescription
EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitorAn EC 4.3.1.* (ammonia-lyase) inhibitor that interferes with the action of diaminopropionate ammonia-lyase (EC 4.3.1.15).
fundamental metaboliteAny metabolite produced by all living cells.
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
L-alpha-amino acidAny alpha-amino acid having L-configuration at the alpha-carbon.
alanineAn alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
pyruvate family amino acidAn L-alpha-amino acid which is biosynthesised from pyruvate (i.e. alanine, valine, and leucine). A closed class.
proteinogenic amino acidAny of the 23 alpha-amino acids that are precursors to proteins, and are incorporated into proteins during translation. The group includes the 20 amino acids encoded by the nuclear genes of eukaryotes together with selenocysteine, pyrrolysine, and N-formylmethionine. Apart from glycine, which is non-chiral, all have L configuration.
alanine zwitterionAn amino acid zwitterion arising from transfer of a proton from the carboxy to the amino group of alanine; major species at pH 7.3.
alpha-amino acidAn amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (84)

PathwayProteinsCompounds
Alanine Metabolism513
Selenoamino Acid Metabolism1226
Urea Cycle1325
Glycine and Serine Metabolism2452
Glutamate Metabolism2244
Glutathione Metabolism1121
Tryptophan Metabolism1855
Glucose-Alanine Cycle810
Primary Hyperoxaluria Type I513
Pyruvate Carboxylase Deficiency513
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Glutathione Synthetase Deficiency1121
5-Oxoprolinuria1121
gamma-Glutamyltransferase Deficiency1121
Lactic Acidemia513
Argininemia1325
Argininosuccinic Aciduria1325
Citrullinemia Type I1325
Ornithine Transcarbamylase Deficiency (OTC Deficiency)1325
Carbamoyl Phosphate Synthetase Deficiency1325
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Non-Ketotic Hyperglycinemia2452
2-Hydroxyglutric Aciduria (D and L Form)2244
Hyperglycinemia, Non-Ketotic2452
5-Oxoprolinase Deficiency1121
gamma-Glutamyltranspeptidase Deficiency1121
Succinic Semialdehyde Dehydrogenase Deficiency2244
3-Phosphoglycerate Dehydrogenase Deficiency2452
D-Alanine Metabolism611
D-Glutamine and D-Glutamate Metabolism1517
Inner Membrane Transport7862
L-Alanine Metabolism1016
tRNA Charging5227
tRNA Charging 22225
Peptidoglycan Biosynthesis I3036
Peptidoglycan Biosynthesis II3037
Glutaminolysis and Cancer3536
Glycine Metabolism1127
NAD Metabolism1435
Glutamic Acid Metabolism1317
Thio-Molybdenum Cofactor Biosynthesis717
Butanoate Metabolism922
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
L-Alanine + 2-Oxo-glutaric acid = Pyruvic acid + L-Glutamic acid ( Glycolysis and Gluconeogenesis )24
L-Alanine + Glyoxylic acid = Pyruvic acid + Glycine ( Glycolysis and Gluconeogenesis )24
Glutamic acid and Glutamine metabolism ( Glutamic acid and Glutamine metabolism )1926
Glycine and Serine metabolism ( Glycine and Serine metabolism )3649
L-Serine + Pyruvic acid = Hydroxy-pyruvic acid + L-Alanine ( Glycine and Serine metabolism )14
Tryptophan degradation ( Tryptophan degradation )6454
Amino acid metabolism pathway excerpt: histidine catabolism extension016
Protein Synthesis: Alanine804
Peptidoglycan cytoplasmic synthesis and recycling pathways834
mRNA, protein, and metabolite inducation pathway by cyclosporin A213
Biosynthesis and turnover of 1-deoxy-sphingoid bases013
Metabolic Epileptic Disorders2589
IAA biosynthesis I025
pyridoxamine anabolism08
NAD biosynthesis II (from tryptophan)024
alanine biosynthesis III02
alanine biosynthesis II04
tRNA charging pathway023
tryptophan degradation I (via anthranilate)09
peptidoglycan and lipid A precursor biosynthesis034
superpathway of alanine biosynthesis08
UDP-N-acetylmuramoyl-pentapeptide biosynthesis III (meso-DAP-containing)020
alanine biosynthesis I07
Phenylalanine biosynthesis08
Glycine biosynthesis04
Tryptophan degradation via kynurenine08
De novo NAD biosynthesis01
AtMetExpress overview0109
NAD biosynthesis II from tryptophan024
Alanine and aspartate metabolism015
Biochemical pathways: part I0466
Amino acid metabolism094
Krebs cycle disorders1214
Proximal tubule transport021
Synthesis of ceramides and 1-deoxyceramides115
Amino acid transport defects (IEMs)925
Cori cycle121

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.35480.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency2.51190.004023.8416100.0000AID485290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)198.00000.00071.600310.0000AID143614
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)KA54.00000.02001.72197.4000AID50347
Carbonic anhydrase 2Homo sapiens (human)KA150.00000.01101.42737.8000AID47753
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
D-alanine biosynthetic processAlanine racemase, biosyntheticEscherichia coli K-12
alanine metabolic processAlanine racemase, biosyntheticEscherichia coli K-12
regulation of cell shapeAlanine racemase, biosyntheticEscherichia coli K-12
peptidoglycan biosynthetic processAlanine racemase, biosyntheticEscherichia coli K-12
D-alanine biosynthetic processAlanine racemase, biosyntheticEscherichia coli K-12
cell wall organizationAlanine racemase, biosyntheticEscherichia coli K-12
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
alanine racemase activityAlanine racemase, biosyntheticEscherichia coli K-12
isomerase activityAlanine racemase, biosyntheticEscherichia coli K-12
pyridoxal phosphate bindingAlanine racemase, biosyntheticEscherichia coli K-12
protein homodimerization activityAlanine racemase, biosyntheticEscherichia coli K-12
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolAlanine racemase, biosyntheticEscherichia coli K-12
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
side of membraneCarbonic anhydrase 4Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID22736Ischemic myocardial half-life measured after intracoronary injection of [13N]-labeled amino acid in dogs (control - 88+/-2)1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
13N-labeled L-amino acids for in vivo assessment of local myocardial metabolism.
AID1654587Substrate activity at Escherichia coli B alanine racemase assessed as Km2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID47753Tested in vitro for activation of Human cloned isozyme carbonic anhydrase II (hCA II)2002Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8
Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID722331Drug uptake in human RBC assessed as membrane localization at 9 uM after 10 to 30 mins by confocal microscopic analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID58930Ischemic myocardial residue fraction of [13N]-labeled amino acid was observed with a single pass uptake technique in open-chest instrumented dogs (control - 18.5+/-2.1)1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
13N-labeled L-amino acids for in vivo assessment of local myocardial metabolism.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID143614Inhibitory concentration required to inhibit [3H]strychnine binding to N-methyl-D-aspartate glutamate receptor 11992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Beta-proline analogues as agonists at the strychnine-sensitive glycine receptor.
AID1276179Induction of insulin release in rat BRIN-BD11 cells at 10 mM after 20 mins measured per 10'6 cells by radioimmunoassay in presence of 5.6 mM glucose (Rvb = 0.97 to 1.05 ng)2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Conformational Analysis of the Host-Defense Peptides Pseudhymenochirin-1Pb and -2Pa and Design of Analogues with Insulin-Releasing Activities and Reduced Toxicities.
AID143466Inhibition of binding of [3H]strychnine to N-methyl-D-aspartate glutamate receptor 1 in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Evaluation and synthesis of aminohydroxyisoxazoles and pyrazoles as potential glycine agonists.
AID33397Km value for Alanine racemase from Pseudomonas aeruginosa1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
(beta-Chloro-alpha-aminoethyl)phosphonic acids as inhibitors of alanine racemase and D-alanine:D-alanine ligase.
AID48116Tested in vitro for activation of carbonic anhydrase IV (bCA IV), purified from bovine lung microsomes2002Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8
Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID1881860Inhibition of PKM2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID722314Drug uptake in Escherichia coli ATCC 10536 assessed as membrane localization at 3 uM after 30 mins by confocal microscopic analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID1329256Induction of increase in glucose-induced insulin secretion in rat BRIN-BD11 cells assessed as insulin release per million cells at 10 mM after 20 mins by radioimmunoassay (Rvb = 1 +/- 0.03 ng)2016Journal of natural products, 09-23, Volume: 79, Issue:9
Purification, Conformational Analysis, and Properties of a Family of Tigerinin Peptides from Skin Secretions of the Crowned Bullfrog Hoplobatrachus occipitalis.
AID1654586Substrate activity at Escherichia coli B alanine racemase assessed as Vmax2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID50347Tested in vitro for activation of Human cloned isozyme carbonic anhydrase I (hCA I)2002Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8
Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID722305Binding affinity to PC/Chol lipid vesicles assessed as decrease in acrylamide-induced tryptophan fluorescence quenching at 1 uM2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID553520Drug uptake in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID722308Induction of dissipation of diffusion potential in PC/Chol lipid vesicles by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722292Binding affinity to LPS assessed as inhibition of LPS-induced LAL enzyme activation at 9 uM after 30 mins by spectrophotometric analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID722319Antifungal activity against Cryptococcus neoformans after 72 hrs by NCCLS microbroth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722310Bactericidal activity against Staphylococcus aureus ATCC 9144 assessed as induction of membrane depolarization at up to 7 uM by DiSC3(5) staining-based fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722312Bactericidal activity against Escherichia coli ATCC 10536 assessed as induction of membrane damage at 5 uM after 30 mins by propidium iodide staining-based flow cytometric analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722329Cytotoxicity against human RBC assessed as hemolysis at 60 uM2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722320Antifungal activity against Candida albicans after 48 hrs by NCCLS microbroth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722322Antibacterial activity against Pseudomonas aeruginosa ATCC BAA-427 after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID553522Drug uptake in Saccharomyces cerevisiae ADMDR1 expressing Candida albicans MDR1 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID722313Cytotoxicity against human RBC assessed as induction of membrane damage at 25 uM after 5 mins by annexin V-FITC staining-based FACS flow cytometric analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID553518Drug uptake in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID722326Antibacterial activity against Staphylococcus epidermidis NRRL B-4268 after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722315Antifungal activity against Aspergillus fumigatus after 72 hrs by NCCLS microbroth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID51033Concentration required for obtaining 50% of the fluorescence intensity of copper-free calcein 1, in bovine serum albumin2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
A green fluorescent chemosensor for amino acids provides a versatile high-throughput screening (HTS) assay for proteases.
AID722324Antibacterial activity against Escherichia coli ATCC 10536 after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722311Cytotoxicity against human RBC assessed as induction of membrane depolarization at up to 16 uM by DiSC3(5) staining-based fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID233320Bitter threshold value; NB denotes 'Not bitter'1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID722307Binding affinity to PE/PG lipid vesicles assessed as induction of large blue shift at 1 uM by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722299Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 6 uM by Griess method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722318Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by NCCLS microbroth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722294Binding affinity to FITC-tagged LPS assessed as induction of disintegration up to 40 uM by circular dichroism analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722328Cytotoxicity against mouse 3T3 cells assessed as cell viability up to 25 uM by MTT assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722295Binding affinity to LPS assessed as increase in helical structure at 36 uM by circular dichroism analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722038Binding affinity to LPS assessed as inhibition of LPS-induced LAL enzyme activation at 18 uM after 30 mins by spectrophotometric analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722304Binding affinity to PE/PG lipid vesicles assessed as decrease in decrease in acrylamide-induced tryptophan fluorescence quenching at 1 uM2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722309Induction of dissipation of diffusion potential in PE/PG lipid vesicles by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID553534Drug accumulation in Saccharomyces cerevisiae AD12345678 reenergized with glucose at pH 6.0 assessed as intracellular accumulation after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID722306Binding affinity to PC/Chol lipid vesicles assessed as induction of large blue shift at 1 uM by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722330Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha secretion at 1.5 to 4.5 uM after 12 hrs by ELISA2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID224503Effect on rate of GTP hydrolysis in the GTP binding protein ras p211998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Prediction of the GTPase activities by using the semiempirical molecular orbital theory.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID722321Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722296Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL6 secretion at 1.5 to 4.5 uM after 12 hrs by ELISA2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722293Binding affinity to LPS assessed as inhibition of LPS-induced LAL enzyme activation at 4.5 uM after 30 mins by spectrophotometric analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID553535Drug accumulation in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump reenergized with glucose at pH 6.0 assessed as intracellular accumulation after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553516Drug uptake in Saccharomyces cerevisiae AD12345678 at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553536Drug accumulation in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump reenergized with glucose at pH 6.0 after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID722327Antibacterial activity against Staphylococcus aureus ATCC 9144 after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722323Antibacterial activity against methicillin-resistant Staphylococcus aureus after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722297Antiinflammatory activity in mouse RAW264.7 cells assessed as downregulation of LPS-induced iNOS2 expression at 4.5 uM after 24 hrs by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722325Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by broth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722298Antiinflammatory activity in mouse RAW264.7 cells assessed as downregulation of LPS-induced TNFalpha expression at 4.5 uM after 24 hrs by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722316Antifungal activity against Trichophyton mentagrophytes after 96 hrs by NCCLS microbroth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
AID722317Antifungal activity against Sporothrix schenckii after 72 hrs by NCCLS microbroth dilution method2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23,789)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908392 (35.28)18.7374
1990's3640 (15.30)18.2507
2000's5791 (24.34)29.6817
2010's3706 (15.58)24.3611
2020's2260 (9.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.12 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index204.68 (26.88)
Search Engine Supply Index2.84 (0.95)

This Compound (85.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials512 (2.09%)5.53%
Trials0 (0.00%)5.53%
Reviews806 (3.29%)6.00%
Reviews0 (0.00%)6.00%
Case Studies441 (1.80%)4.05%
Case Studies0 (0.00%)4.05%
Observational72 (0.29%)0.25%
Observational0 (0.00%)0.25%
Other22,637 (92.52%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]